SILICONE-BASED OPHTHALMIC FORMULATIONS

Abstract
Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.
Description
BACKGROUND OF THE INVENTION

The eye can be inflicted with diseases and conditions which require specialized medical treatments (See Afshari, N., Research in cornea and external disease in refining current concept and branching out into new avenues of investigation, Rev Ophthalmol Online, April 2006, 5 (13); and Schroeder, I., et al., Development and characterization of film forming polymeric solutions for skin drug delivery, European Journal of Pharmaceutics and Biopharmaceutics, January 2007, 65 (1), p. 111-121). In order to effectively deliver a pharmaceutically active composition to the eye, appropriate vehicles are required. There is a need in the field for effective ophthalmic vehicles (e.g. excipients), which are chemically and biologically inert, have a low surface tension (e.g. good spreading characteristics on water), enable the solubility of hydrophobic drugs and maintain drug efficacy without side effects. The present invention solves these as well as other problems in the art by, inter alia, providing silicone based topical ophthalmic formulations for application to the region on and around the eye (i.e. conjunctiva, lacrima tissue or cornea) and maintaining efficacy without side effects.


BRIEF SUMMARY OF THE INVENTION

Presented herein inter alia are compositions containing silicone based excipients for ophthalmic application as well as methods of treating ophthalmic diseases and methods of improving vision. In certain embodiments, the compositions and methods are useful for treating the symptoms of glaucoma and include a combination of active pharmaceutical ingredients and a silicone excipient.


In one aspect, a composition including an active pharmaceutical ingredient and a silicone excipient is provided.


In another aspect, a method of treating an ophthalmic disease in a subject in need thereof is provided. The method includes administering to the subject an active pharmaceutical ingredient and a silicone excipient.


In another aspect, a method of improving vision in a subject in need thereof is provided. The method includes administering to the subject an active pharmaceutical ingredient and a silicone excipient.


Some embodiments of the invention include the following:


Embodiment 1. A composition comprising an active pharmaceutical ingredient and a silicone excipient.


Embodiment 2. The composition of embodiment 1, wherein said active pharmaceutical ingredient is an immunosuppressant, a vasodilator agent, an anti-inflammatory agent, an EP2 receptor agonist, a muscarinic receptor agonist, a prostaglandin analog, a vasoconstrictor agent, or an anti-infective agent.


Embodiment 3. The composition of embodiment 1, wherein said composition is an ophthalmic pharmaceutical formulation.


Embodiment 4. The composition of embodiment 1, wherein said active pharmaceutical ingredient is an immunosuppressant


Embodiment 5. The composition of embodiment 4, wherein said immunosuppressant is cyclosporine.


Embodiment 6. The composition of embodiment 5, wherein said cyclosporine is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 7. The composition of embodiment 5, wherein said cyclosporine is present in an amount of about 0.01% w/w


Embodiment 8. The composition of embodiment 4, wherein said immunosuppressant is tacrolimus.


Embodiment 9. The composition of embodiment 8, wherein said tacrolimus is present in an amount approximately equal to or less than about 4% w/w.


Embodiment 10. The composition of embodiment 8, wherein said tacrolimus is present in an amount of about 0.001% w/w.


Embodiment 11. The composition of embodiment 1, wherein said active pharmaceutical ingredient is a vasodilator agent.


Embodiment 12. The composition of embodiment 11, wherein said vasodilator agent is an alpha adrenergic antagonist


Embodiment 13. The composition of embodiment 12, wherein said alpha adrenergic antagonist is phentolamine.


Embodiment 14. The composition of embodiment 12, wherein said phentolamine is present in an amount approximately equal to or less than about 4% w/w


Embodiment 15. The composition of embodiment 12, wherein said phentolamine is present in an amount of about 0.001% w/w


Embodiment 16. The composition of embodiment 1, wherein said active pharmaceutical ingredient is an anti-inflammatory agent.


Embodiment 17. The composition of embodiment 16, wherein said anti-inflammatory agent is a non-steroidal anti-inflammatory agent.


Embodiment 18. The composition of embodiment 17, wherein said non-steroidal anti-inflammatory agent is ketorolac.


Embodiment 19. The composition of embodiment 18, wherein said ketorolac is present in an amount approximately equal to or less than about 2% w/w.


Embodiment 20. The composition of embodiment 18, wherein said ketorolac is present in an amount of about 0.01% w/w.


Embodiment 21. The composition of embodiment 16, wherein said anti-inflammatory agent is testosterone.


Embodiment 22. The composition of embodiment 21, wherein said testosterone is present in an amount approximately equal to or less than about 5% w/w.


Embodiment 23. The composition of embodiment 21, wherein said testosterone is present in an amount of about 0.001% w/w.


Embodiment 24. The composition of embodiment 16, wherein said anti-inflammatory agent is dihydrotestosterone.


Embodiment 25. The composition of embodiment 24, wherein said dihydrotestosterone is present in an amount approximately equal to or less than about 5% w/w.


Embodiment 26. The composition of embodiment 24, wherein said dihydrotestosterone is present in an amount of about 0.001% w/w.


Embodiment 27. The composition of embodiment 16, wherein said anti-inflammatory agent is testosterone propionate.


Embodiment 28. The composition of embodiment 27, wherein said testosterone propionate is present in an amount approximately equal to or less than about 5% w/w.


Embodiment 29. The composition of embodiment 27, wherein said testosterone propionate is present in an amount of about 0.001% w/w.


Embodiment 30. The composition of embodiment 16, wherein said anti-inflammatory agent is dexamethasone.


Embodiment 31. The composition of embodiment 30, wherein said dexamethasone is present in amount approximately equal to or less than about 5% w/w.


Embodiment 32. The composition of embodiment 30, wherein said dexamethasone is present in an amount of about 0.001% w/w.


Embodiment 33. The composition of embodiment 16, wherein said anti-inflammatory agent is prednisolone.


Embodiment 34. The composition of embodiment 33, wherein said prednisolone is present in amount approximately equal to or less than about 5% w/w.


Embodiment 35. The composition of embodiment 33, wherein said prednisolone is present in amount of about 0.001% w/w.


Embodiment 36. The composition of embodiment 1, wherein said active pharmaceutical ingredient is an EP2 receptor agonist.


Embodiment 37. The composition of embodiment 36, wherein said EP2 receptor agonist has the formula




embedded image


Embodiment 38. The composition of embodiment 37, wherein said EP2 receptor agonist is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 39. The composition of embodiment 37, wherein said EP2 receptor agonist is present in an amount of about 0.001% w/w.


Embodiment 40. The composition of embodiment 36, wherein said EP2 receptor agonist has the formula




embedded image


Embodiment 41. The composition of embodiment 40, wherein said EP2 receptor agonist is present in an amount approximately equal to or less than about 0.05% w/w.


Embodiment 42. The composition of embodiment 40, wherein said EP2 receptor agonist is present in an amount of about 0.0002% w/w.


Embodiment 43. The composition of embodiment 36, wherein said EP2 receptor agonist has the formula




embedded image


Embodiment 44. The composition of embodiment 43, wherein EP2 receptor agonist is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 45. The composition of embodiment 43, wherein said EP2 receptor agonist is present in an amount of about 0.001% w/w.


Embodiment 46. The composition of embodiment 1, wherein said active pharmaceutical ingredient is a muscarinic receptor agonist.


Embodiment 47. The composition of embodiment 46, wherein said muscarinic receptor agonist is pilocarpine.


Embodiment 48. The composition of embodiment 47, wherein said pilocarpine is present in an amount approximately equal to or less than about 6% w/w.


Embodiment 49. The composition of embodiment 47, wherein said pilocarpine is present in an amount of about 0.1% w/w.


Embodiment 50. The composition of embodiment 1, wherein said active pharmaceutical ingredient is a prostaglandin analog.


Embodiment 51. The composition of embodiment 50, wherein said prostaglandin analog is bimatoprost.


Embodiment 52. The composition of embodiment 51, wherein said bimatoprost is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 53. The composition of embodiment 51, wherein said bimatoprost is present in an amount of about 0.001% w/w.


Embodiment 54. The composition of embodiment 50, wherein said prostaglandin analog is latanoprost.


Embodiment 55. The composition of embodiment 54, wherein said latanoprost is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 56. The composition of embodiment 54, wherein said latanoprost is present in an amount of about 0.0003% w/w.


Embodiment 57. The composition of embodiment 50, wherein said prostaglandin analog is travoprost.


Embodiment 58. The composition of embodiment 57, wherein said travoprost is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 59. The composition of embodiment 57, wherein said travoprost is present in an amount of about 0.0002% w/w.


Embodiment 60. The composition of embodiment 1, wherein said active pharmaceutical ingredient is a vasoconstrictor agent.


Embodiment 61. The composition of embodiment 60, wherein said vasoconstrictor agent is an alpha adrenergic agonist.


Embodiment 62. The composition of embodiment 61, wherein said alpha adrenergic agonist is brimonidine.


Embodiment 63. The composition of embodiment 62, wherein said brimonidine is present in an amount approximately equal to or less than 1% w/w.


Embodiment 64. The composition of embodiment 62, wherein said brimonidine is present in an amount of about 0.001% w/w.


Embodiment 65. The composition of embodiment 61, wherein said alpha adrenergic agonist is an alpha adrenergic agonist compound.


Embodiment 66. The composition of embodiment 65, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 67. The composition of embodiment 65, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 68. The composition of embodiment 65, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 69. The composition of embodiment 65, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 70. The composition of embodiment 65, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 71. The composition of embodiment 65, wherein said alpha adrenergic agonist compound is present in an amount approximately equal to or less than 1% w/w.


Embodiment 72. The composition of embodiment 65, wherein said alpha adrenergic agonist compound is present in an amount of about 0.001% w/w.


Embodiment 73. The composition of embodiment 60, wherein said vasoconstrictor agent is a beta adrenergic antagonist.


Embodiment 74. The composition of embodiment 73, wherein said beta adrenergic antagonist is timolol.


Embodiment 75. The composition of embodiment 74, wherein said timolol is present in an amount approximately equal to or less than about 0.5% w/w.


Embodiment 76. The composition of embodiment 74, wherein said timolol is present in amount of about 0.05% w/w.


Embodiment 77. The composition of embodiment 1, wherein said active pharmaceutical ingredient is an anti-infective agent.


Embodiment 78. The composition of embodiment 77, wherein said anti-infective agent is gatifloxacin.


Embodiment 79. The composition of embodiment 78, wherein said gatifloxacin is present in an amount approximately equal to or less than about 1% w/w.


Embodiment 80. The composition of embodiment 78, wherein said gatifloxacin is present in an amount of about 0.1% w/w.


Embodiment 81. The composition of embodiment 1, wherein said silicone excipient forms part of a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, fourth silicone excipient blend or a fifth silicone excipient blend.


Embodiment 82. The composition of embodiment 81, wherein said composition comprises a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend and a fourth silicone excipient blend.


Embodiment 83. The composition of embodiment 81, wherein said first silicone excipient blend comprises a mixture of dimethicone and dimethiconol.


Embodiment 84. The composition of embodiment 81, wherein said first silicone excipient blend is present from about 5% w/w to about 10% w/w.


Embodiment 85. The composition of embodiment 81, wherein said second silicone excipient blend comprises a mixture of cyclopentasiloxane and a dimethicone cross polymer.


Embodiment 86. The composition of embodiment 86, wherein said second silicone excipient blend is present from about 5% w/w to about 10% w/w.


Embodiment 87. The composition of embodiment 81, wherein said third silicone excipient blend comprises a mixture of polydimethylcyclosiloxanes.


Embodiment 88. The composition of embodiment 87, wherein said third silicone excipient blend is present from about 5% w/w to about 10% w/w.


Embodiment 89. The composition of embodiment 81, wherein said fourth silicone excipient blend comprises a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene.


Embodiment 90. The composition of embodiment 89, wherein said fourth silicone excipient blend is present from about 2% w/w to about 5% w/w.


Embodiment 91. The composition of embodiment 81, wherein said fifth silicone excipient blend comprises a mixture of stearyloxytrimethylsilane and stearyl alcohol.


Embodiment 92. The composition of embodiment 91, wherein said fifth silicone excipient blend is present at about 5% w/w.


Embodiment 93. The composition of embodiment 1, further comprising a salt, a tonicity agent, a lipid excipient or a thickening agent.


Embodiment 94. The composition of embodiment 1, further comprising a salt, a tonicity agent, a lipid excipient and a thickening agent.


Embodiment 95. The composition of embodiment 93, wherein said salt is sodium chloride.


Embodiment 96. The composition of embodiment 93, wherein said salt is sodium hydroxide.


Embodiment 97. The composition of embodiment 93, wherein said salt is present from about 0.5% w/w to about 1% w/w.


Embodiment 98. The composition of embodiment 93, wherein said tonicity agent is glycerin.


Embodiment 99. The composition of embodiment 98, wherein said tonicity agent is present from about 0.5% w/w to about 6% w/w.


Embodiment 100. The composition of embodiment 93, wherein said lipid excipient is mineral oil.


Embodiment 101. The composition of embodiment 100, wherein said mineral oil is present from about 0.5% w/w to about 12% w/w.


Embodiment 102. The composition of embodiment 93, wherein said lipid excipient is capric/caprylic triglyceride.


Embodiment 103. The composition of embodiment 102, wherein said capric/caprylic triglyceride is present from about 5% w/w to about 12% w/w.


Embodiment 104. The composition of embodiment 93, wherein said thickening agent is a carbomer.


Embodiment 105. The composition of embodiment 104, wherein said carbomer is present from about 0.5% w/w to about 1% w/w.


Embodiment 106. The composition of embodiment 1, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 107. The composition of embodiment 106, wherein cyclosporine is present from 0.01% w/w about to about 0.1% w/w


Embodiment 108. The composition of embodiment 106, wherein tacrolimus is present from about 0.01% w/w to about 0.1% w/w.


Embodiment 109. The composition of embodiment 106, wherein phentolamine is present from about 0.0001% w/w to about 1% w/w.


Embodiment 110. The composition of embodiment 106, wherein testosterone is present from about 0.001% w/w to about 5% w/w.


Embodiment 111. The composition of embodiment 106, wherein dihydrotestosterone is present from about 0.001% w/w to about 5% w/w.


Embodiment 112. The composition of embodiment 106, wherein testosterone propionate is present from about 0.001% w/w to about 5% w/w.


Embodiment 113. The composition of embodiment 106, wherein said EP2 receptor agonist has the Formula




embedded image


Embodiment 114. The composition of embodiment 113, wherein said EP2 receptor agonist is present from about 0.001% w/w to about 0.1% w/w.


Embodiment 115. The composition of embodiment 106, wherein said EP2 receptor agonist has the Formula




embedded image


Embodiment 116. The composition of embodiment 115, wherein said EP2 receptor agonist is present from about 0.0002% w/w to about 0.05% w/w.


Embodiment 117. The composition of claim 1, consisting essentially of an active pharmaceutical ingredient selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin; a salt, a tonicity agent, a lipid excipient, a thickening agent, and a silicone excipient.


Embodiment 118. The composition of embodiment 3, wherein said ophthalmic pharmaceutical formulation is a cream formulation.


Embodiment 119. The composition of embodiment 118, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 120. The composition of embodiment 119, wherein said silicone excipient is a first silicone blend, a second silicone blend, a third silicone blend and a fourth silicone blend.


Embodiment 121. The composition of embodiment 120, further comprising a salt, a tonicity agent, and a lipid excipient.


Embodiment 122. The composition of embodiment 120, further comprising a salt and a tonicity agent.


Embodiment 123. The composition of embodiment 3, wherein said ophthalmic pharmaceutical formulation is a gel formulation.


Embodiment 124. The composition of embodiment 123, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 125. The composition of embodiment 124, wherein said silicone excipient is a blend of stearyloxytrimethylsilane and stearyl alcohol.


Embodiment 126. The composition of embodiment 125, further comprising a thickening agent, a salt, a tonicity agent, and a lipid excipient.


Embodiment 127. The composition of embodiment 3, wherein said ophthalmic pharmaceutical formulation is an emulsion formulation.


Embodiment 128. The composition of embodiment 127, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 129. The composition of embodiment 128, wherein said silicone excipient is a blend of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene.


Embodiment 130. The composition of embodiment 129, further comprising a lipid excipient, a salt, and a tonicity agent.


Embodiment 131. A method of treating an ophthalmic disease in a subject in need thereof, said method comprising administering to said subject an active pharmaceutical ingredient and a silicone excipient.


Embodiment 132. The method of embodiment 131, wherein said ophthalmic disease is central retinal vein occlusion.


Embodiment 133. The method of embodiment 131, wherein said ophthalmic disease is branch retinal vein occlusion.


Embodiment 134. The method of embodiment 131, wherein said ophthalmic disease is choroidal macular edema.


Embodiment 135. The method of embodiment 131, wherein said ophthalmic disease is diabetic macular edema.


Embodiment 136. The method of embodiment 131, wherein said ophthalmic disease is diabetic macular retinopathy.


Embodiment 137. The method of embodiment 131, wherein said ophthalmic disease is uveitis.


Embodiment 138. The method of embodiment 131, wherein said ophthalmic disease is age related macular degeneration.


Embodiment 139. The method of embodiment 131, wherein said ophthalmic disease is glaucoma.


Embodiment 140. The method of embodiment 131, wherein said ophthalmic disease is ocular hypertension.


Embodiment 141. A method of improving vision in a subject in need thereof, said method comprising administering to said subject an active pharmaceutical ingredient and a silicone excipient.


Embodiment 142 A non-aqueous composition comprising an active pharmaceutical ingredient and a silicone excipient.


Embodiment 143. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is an immunosuppressant, a vasodilator agent, an anti-inflammatory agent, an EP2 receptor agonist, a muscarinic receptor agonist, a prostaglandin analog, a vasoconstrictor agent, or an anti-infective agent.


Embodiment 144. The non-aqueous composition of embodiment 142, wherein said composition is an ophthalmic pharmaceutical formulation.


Embodiment 145. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is an immunosuppressant


Embodiment 146. The non-aqueous composition of embodiment 145, wherein said immunosuppressant is cyclosporine.


Embodiment 147. The non-aqueous composition of embodiment 146, wherein said cyclosporine is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 148. The non-aqueous composition of embodiment 146, wherein said cyclosporine is present in an amount of about 0.01% w/w


Embodiment 149. The non-aqueous composition of embodiment 145, wherein said immunosuppressant is tacrolimus.


Embodiment 150. The non-aqueous composition of embodiment 149, wherein said tacrolimus is present in an amount approximately equal to or less than about 4% w/w.


Embodiment 151. The non-aqueous composition of embodiment 149, wherein said tacrolimus is present in an amount of about 0.001% w/w.


Embodiment 152. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is a vasodilator agent.


Embodiment 153. The non-aqueous composition of embodiment 152, wherein said vasodilator agent is an alpha adrenergic antagonist


Embodiment 154. The non-aqueous composition of embodiment 153, wherein said alpha adrenergic antagonist is phentolamine.


Embodiment 155. The non-aqueous composition of embodiment 153, wherein said phentolamine is present in an amount approximately equal to or less than about 4% w/w


Embodiment 156. The non-aqueous composition of embodiment 153, wherein said phentolamine is present in an amount of about 0.001% w/w


Embodiment 157. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is an anti-inflammatory agent.


Embodiment 158. The non-aqueous composition of embodiment 157, wherein said anti-inflammatory agent is a non-steroidal anti-inflammatory agent.


Embodiment 159. The non-aqueous composition of embodiment 1158, wherein said non-steroidal anti-inflammatory agent is ketorolac.


Embodiment 160. The non-aqueous composition of embodiment 159, wherein said ketorolac is present in an amount approximately equal to or less than about 2% w/w.


Embodiment 161. The non-aqueous composition of embodiment 159, wherein said ketorolac is present in an amount of about 0.01% w/w.


Embodiment 162. The non-aqueous composition of embodiment 157, wherein said anti-inflammatory agent is testosterone.


Embodiment 163. The non-aqueous composition of embodiment 162, wherein said testosterone is present in an amount approximately equal to or less than about 5% w/w.


Embodiment 164. The non-aqueous composition of embodiment 162, wherein said testosterone is present in an amount of about 0.001% w/w.


Embodiment 165. The non-aqueous composition of embodiment 157, wherein said anti-inflammatory agent is dihydrotestosterone.


Embodiment 166. The non-aqueous composition of embodiment 165, wherein said dihydrotestosterone is present in an amount approximately equal to or less than about 5% w/w.


Embodiment 167. The non-aqueous composition of embodiment 165, wherein said dihydrotestosterone is present in an amount of about 0.001% w/w.


Embodiment 168. The non-aqueous composition of embodiment 157, wherein said anti-inflammatory agent is testosterone propionate.


Embodiment 169. The non-aqueous composition of embodiment 168, wherein said testosterone propionate is present in an amount approximately equal to or less than about 5% w/w.


Embodiment 170. The non-aqueous composition of embodiment 168, wherein said testosterone propionate is present in an amount of about 0.001% w/w.


Embodiment 171. The non-aqueous composition of embodiment 157, wherein said anti-inflammatory agent is dexamethasone.


Embodiment 172. The non-aqueous composition of embodiment 171, wherein said dexamethasone is present in amount approximately equal to or less than about 5% w/w.


Embodiment 173. The non-aqueous composition of embodiment 171, wherein said dexamethasone is present in an amount of about 0.001% w/w.


Embodiment 174. The non-aqueous composition of embodiment 157, wherein said anti-inflammatory agent is prednisolone.


Embodiment 175. The non-aqueous composition of embodiment 174, wherein said prednisolone is present in amount approximately equal to or less than about 5% w/w.


Embodiment 176. The non-aqueous composition of embodiment 174, wherein said prednisolone is present in amount of about 0.001% w/w.


Embodiment 177. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is an EP2 receptor agonist.


Embodiment 178. The non-aqueous composition of embodiment 177, wherein said EP2 receptor agonist has the formula




embedded image


Embodiment 179. The non-aqueous composition of embodiment 178, wherein said EP2 receptor agonist is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 180. The non-aqueous composition of embodiment 178, wherein said EP2 receptor agonist is present in an amount of about 0.001% w/w.


Embodiment 181. The non-aqueous composition of embodiment 177, wherein said EP2 receptor agonist has the formula




embedded image


Embodiment 182. The non-aqueous composition of embodiment 181, wherein said EP2 receptor agonist is present in an amount approximately equal to or less than about 0.05% w/w.


Embodiment 183. The non-aqueous composition of embodiment 181, wherein said EP2 receptor agonist is present in an amount of about 0.0002% w/w.


Embodiment 184. The non-aqueous composition of embodiment 177, wherein said EP2 receptor agonist has the formula




embedded image


Embodiment 185. The non-aqueous composition of embodiment 184, wherein EP2 receptor agonist is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 186. The non-aqueous composition of embodiment 184, wherein said EP2 receptor agonist is present in an amount of about 0.001% w/w.


Embodiment 187. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is a muscarinic receptor agonist.


Embodiment 188. The non-aqueous composition of embodiment 187, wherein said muscarinic receptor agonist is pilocarpine.


Embodiment 189. The non-aqueous composition of embodiment 188, wherein said pilocarpine is present in an amount approximately equal to or less than about 6% w/w.


Embodiment 190. The non-aqueous composition of embodiment 188, wherein said pilocarpine is present in an amount of about 0.1% w/w.


Embodiment 191. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is a prostaglandin analog.


Embodiment 192. The non-aqueous composition of embodiment 191, wherein said prostaglandin analog is bimatoprost.


Embodiment 193. The non-aqueous composition of embodiment 192, wherein said bimatoprost is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 194. The non-aqueous composition of embodiment 192, wherein said bimatoprost is present in an amount of about 0.001% w/w.


Embodiment 195. The non-aqueous composition of embodiment 191, wherein said prostaglandin analog is latanoprost.


Embodiment 196. The non-aqueous composition of embodiment 195, wherein said latanoprost is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 197. The non-aqueous composition of embodiment 195, wherein said latanoprost is present in an amount of about 0.0003% w/w.


Embodiment 198. The non-aqueous composition of embodiment 191, wherein said prostaglandin analog is travoprost.


Embodiment 199. The non-aqueous composition of embodiment 198, wherein said travoprost is present in an amount approximately equal to or less than about 0.1% w/w.


Embodiment 200. The non-aqueous composition of embodiment 198, wherein said travoprost is present in an amount of about 0.0002% w/w.


Embodiment 201. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is a vasoconstrictor agent.


Embodiment 202. The non-aqueous composition of embodiment 201, wherein said vasoconstrictor agent is an alpha adrenergic agonist.


Embodiment 203. The non-aqueous composition of embodiment 202, wherein said alpha adrenergic agonist is brimonidine.


Embodiment 204. The non-aqueous composition of embodiment 203, wherein said brimonidine is present in an amount approximately equal to or less than 1% w/w.


Embodiment 205. The non-aqueous composition of embodiment 203, wherein said brimonidine is present in an amount of about 0.001% w/w.


Embodiment 206. The non-aqueous composition of embodiment 202, wherein said alpha adrenergic agonist is an alpha adrenergic agonist compound.


Embodiment 207. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 208. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 209. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 210. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 211. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound has the Formula




embedded image


Embodiment 212. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound is present in an amount approximately equal to or less than 1% w/w.


Embodiment 213. The non-aqueous composition of embodiment 206, wherein said alpha adrenergic agonist compound is present in an amount of about 0.001% w/w.


Embodiment 214. The non-aqueous composition of embodiment 201, wherein said vasoconstrictor agent is a beta adrenergic antagonist.


Embodiment 215. The non-aqueous composition of embodiment 214, wherein said beta adrenergic antagonist is timolol.


Embodiment 216. The non-aqueous composition of embodiment 215, wherein said timolol is present in an amount approximately equal to or less than about 0.5% w/w.


Embodiment 217. The non-aqueous composition of embodiment 215, wherein said timolol is present in amount of about 0.05% w/w.


Embodiment 218. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is an anti-infective agent.


Embodiment 219. The non-aqueous composition of embodiment 218, wherein said anti-infective agent is gatifloxacin.


Embodiment 220. The non-aqueous composition of embodiment 219, wherein said gatifloxacin is present in an amount approximately equal to or less than about 1% w/w.


Embodiment 221. The non-aqueous composition of embodiment 219, wherein said gatifloxacin is present in an amount of about 0.1% w/w.


Embodiment 222. The non-aqueous composition of embodiment 142, wherein said silicone excipient is a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, fourth silicone excipient blend, a fifth silicone excipient blend, a sixth silicone excipient blend or a seventh silicone excipient blend.


Embodiment 223. The non-aqueous composition of embodiment 222, wherein said composition comprises a first silicone excipient blend and a second silicone excipient blend.


Embodiment 224. The non-aqueous composition of embodiment 222, wherein said composition comprises a first silicone excipient blend, a second silicone excipient blend and a third silicone excipient blend.


Embodiment 225. The non-aqueous composition of embodiment 222, wherein said composition comprises a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend and a fourth silicone excipient blend.


Embodiment 226. The non-aqueous composition of embodiment 222, wherein said first silicone excipient blend comprises a mixture of dimethicone and dimethiconol.


Embodiment 227. The non-aqueous composition of embodiment 226, wherein said first silicone excipient blend is present from about 1% w/w to about 10% w/w.


Embodiment 228. The non-aqueous composition of embodiment 222, wherein said second silicone excipient blend comprises a mixture of cyclopentasiloxane and a dimethicone cross polymer.


Embodiment 229. The non-aqueous composition of embodiment 228, wherein said second silicone excipient blend is present from about 5% w/w to about 20% w/w.


Embodiment 230. The non-aqueous composition of embodiment 222, wherein said third silicone excipient blend comprises a mixture of polydimethylcyclosiloxanes.


Embodiment 231. The non-aqueous composition of embodiment 230, wherein said third silicone excipient blend is present from about 10% w/w to about 30% w/w.


Embodiment 232. The non-aqueous composition of embodiment 222, wherein said fourth silicone excipient blend comprises a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene.


Embodiment 234. The non-aqueous composition of embodiment 232, wherein said fourth silicone excipient blend is present from about 0.5% w/w to about 5% w/w.


Embodiment 235. The non-aqueous composition of embodiment 222, wherein said fifth silicone excipient blend comprises a mixture of stearyloxytrimethylsilane and stearyl alcohol.


Embodiment 236. The non-aqueous composition of embodiment 235, wherein said fifth silicone excipient blend is present from about 5% w/w to about 15% w/w.


Embodiment 237. The non-aqueous composition of embodiment 222, wherein said sixth silicone excipient blend comprises a mixture of dimethiconol and hexamethyldisiloxane.


Embodiment 238. The non-aqueous composition of embodiment 237, wherein said sixth silicone excipient blend is present from about 5% w/w to about 10% w/w.


Embodiment 239. The non-aqueous composition of embodiment 222, wherein said seventh silicone excipient blend comprises alkylmethyl siloxane wax.


Embodiment 240. The non-aqueous composition of embodiment 239, wherein said seventh silicone excipient blend is present from about 5% w/w to about 12% w/w.


Embodiment 241. The non-aqueous composition of embodiment 142, further comprising a plurality of lipid excipients or a thickening agent.


Embodiment 242. The non-aqueous composition of embodiment 142, further comprising a plurality of lipid excipients and a thickening agent.


Embodiment 243. The non-aqueous composition of embodiment 241, wherein said thickening agent is talc.


Embodiment 244. The non-aqueous composition embodiment 243, wherein said talc is present from about 2% w/w to about 5% w/w.


Embodiment 245. The non-aqueous composition of embodiment 142, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 246. The non-aqueous composition of embodiment 245, wherein cyclosporine is present from 0.01% w/w about to about 0.1% w/w.


Embodiment 247. The non-aqueous composition of embodiment 245, wherein tacrolimus is present from about 0.01% w/w to about 0.1% w/w.


Embodiment 248. The non-aqueous composition of embodiment 245, wherein phentolamine is present from about 0.0001% w/w to about 1% w/w.


Embodiment 249. The non-aqueous composition of embodiment 245, wherein testosterone is present from about 0.001% w/w to about 5% w/w.


Embodiment 250. The non-aqueous composition of embodiment 245, wherein dihydrotestosteron is present from about 0.001% w/w to about 5% w/w.


Embodiment 251. The non-aqueous composition of embodiment 245, wherein testosterone propionate is present from about 0.001% w/w to about 5% w/w.


Embodiment 252. The non-aqueous composition of embodiment 245, wherein said EP2 receptor agonist has the Formula




embedded image


Embodiment 253. The non-aqueous composition of embodiment 252, wherein said EP2 receptor agonist is present from about 0.001% w/w to about 0.1% w/w.


Embodiment 254. The non-aqueous composition of embodiment 245, wherein said EP2 receptor agonist has the Formula




embedded image


Embodiment 255. The non-aqueous composition of embodiment 254, wherein said EP2 receptor agonist is present from about 0.0002% w/w to about 0.05% w/w.


Embodiment 256. The non-aqueous composition of embodiment 142, consisting essentially of: an active pharmaceutical ingredient selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin; a plurality of lipid excipients; and one or more silicone excipients.


Embodiment 257. The non-aqueous composition of embodiment 142, consisting essentially of: an active pharmaceutical ingredient selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin; a plurality of lipid excipients; a thickening agent; and one or more silicone excipients.


Embodiment 258. The non-aqueous composition of embodiment 144, wherein said ophthalmic pharmaceutical formulation is an ointment formulation.


Embodiment 259. The non-aqueous composition of embodiment 258, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 260. The non-aqueous composition of embodiment 259, wherein said silicone excipient is a first silicone blend or a second silicone blend.


Embodiment 261. The non-aqueous composition of embodiment 260 comprising a first silicone excipient blend and a second silicone excipient blend.


Embodiment 262. The non-aqueous composition of embodiment 261, wherein said first silicone excipient blend is a mixture of dimethicone and dimethiconol and said second silicone excipient blend is a mixture of alkylmethyl siloxane wax.


Embodiment 263. The non-aqueous composition of embodiment 261, wherein said first silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer and said second silicone excipient blend is a mixture of polydimethylcyclosiloxanes.


Embodiment 264. The non-aqueous composition of embodiment 261, further comprising a lipid excipient.


Embodiment 265. The non-aqueous composition of embodiment 144, wherein said ophthalmic pharmaceutical formulation is a gel formulation.


Embodiment 266. The non-aqueous composition of embodiment 265, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 267. The non-aqueous composition of claim embodiment 266, wherein said silicone excipient is a first silicone excipient blend or a second silicone excipient blend.


Embodiment 268. The non-aqueous composition of embodiment 267 comprising a first silicone excipient blend and a second silicone excipient blend.


Embodiment 269. The non-aqueous composition of embodiment 268, wherein said first silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer and said second silicone excipient blend is a mixture of polydimethylcyclosiloxanes.


Embodiment 270. The non-aqueous composition of embodiment 268, further comprising a lipid excipient.


Embodiment 271. The non-aqueous composition of embodiment 144 wherein said ophthalmic pharmaceutical formulation is a spray formulation.


Embodiment 272. The non-aqueous composition of embodiment 271, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 273. The non-aqueous composition of embodiment 272, wherein said silicone excipient is a silicone excipient blend, said silicone excipient blend comprising a mixture of dimethiconol and hexamethyldisiloxane.


Embodiment 274. The non-aqueous composition of embodiment 273, further comprising a thickening agent.


Embodiment 275. The non-aqueous composition of embodiment 272, wherein said silicone excipient is a first silicone excipient blend or a second silicone excipient blend.


Embodiment 276. The non-aqueous composition of embodiment 272 comprising a first silicone excipient blend and a second silicone excipient blend.


Embodiment 277. The non-aqueous composition of embodiment 276, wherein said first silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer and said second silicone excipient blend is a mixture of dimethiconol and hexamethyldisiloxane.


Embodiment 278. The non-aqueous composition of embodiment 272, wherein said silicone excipient is a first silicone excipient blend, a second silicone excipient blend or a third silicone excipient blend.


Embodiment 279. The non-aqueous composition of embodiment 278 comprising a first silicone excipient blend, a second silicone excipient blend and a third silicone excipient blend.


Embodiment 280. The non-aqueous composition of embodiment 279, wherein said first silicone excipient blend is a mixture of dimethicone and dimethiconol, said second silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer, and said third silicone excipient blend is a mixture of polydimethylcyclosiloxanes.


Embodiment 281. The non-aqueous composition of embodiment 144, wherein said ophthalmic pharmaceutical formulation is a stick formulation.


Embodiment 282. The non-aqueous composition of embodiment 281, wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 283. The non-aqueous composition of embodiment 282, wherein said silicone excipient is an alkylmethyl siloxane wax.


Embodiment 284. The non-aqueous composition of embodiment 283, further comprising a plurality of lipid excipients.


Embodiment 285. The non-aqueous composition of embodiment 282, wherein said silicone excipient is a first silicone excipient blend or a second silicone excipient blend.


Embodiment 286. The non-aqueous composition of embodiment 285, comprising a first silicone excipient blend and a second silicone excipient blend.


Embodiment 287. The non-aqueous composition of embodiment 286, wherein said first silicone excipient blend is a mixture of stearyloxytrimethylsilane and stearyl alcohol, and said second silicone excipient blend is a mixture of polydimethylcyclosiloxanes.


Embodiment 288. The non-aqueous composition of embodiment 287, further comprising a plurality of lipid excipients.


Embodiment 289. The non-aqueous composition of embodiment 144 wherein said ophthalmic pharmaceutical formulation is an emulsion formulation.


Embodiment 290. The non-aqueous composition of embodiment 289 wherein said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, and gatifloxacin.


Embodiment 291. The non-aqueous composition of embodiment 290 wherein said silicone excipient is a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene.


Embodiment 292. The non-aqueous composition of embodiment 291 further comprising a lipid excipient.


Embodiment 293. The non-aqueous composition of embodiment 290 wherein said silicone excipient is a first silicone excipient blend or a second silicone excipient blend.


Embodiment 294. The non-aqueous composition of embodiment 293 comprising a first silicone excipient blend and a second silicone excipient blend.


Embodiment 295. The non-aqueous composition of embodiment 294, wherein said first silicone excipient blend is a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene, and said second silicone excipient blend is a mixture of dimethicone and dimethiconol.


Embodiment 296. The non-aqueous composition of embodiment 295, further comprising a lipid excipient.


Embodiment 297. A method of treating an ophthalmic disease in a subject in need thereof, said method comprising administering to said subject an active pharmaceutical ingredient and a silicone excipient.


Embodiment 298. The method of embodiment 297, wherein said ophthalmic disease is central retinal vein occlusion.


Embodiment 299. The method of embodiment 297, wherein said ophthalmic disease is branch retinal vein occlusion.


Embodiment 300. The method of embodiment 297, wherein said ophthalmic disease is choroidal macular edema.


Embodiment 300. The method of embodiment 297, wherein said ophthalmic disease is diabetic macular edema.


Embodiment 301. The method of embodiment 297, wherein said ophthalmic disease is diabetic macular retinopathy.


Embodiment 302. The method of embodiment 297, wherein said ophthalmic disease is uveitis.


Embodiment 303. The method of embodiment 297, wherein said ophthalmic disease is age related macular degeneration.


Embodiment 163. The method of embodiment 297, wherein said ophthalmic disease is glaucoma.


Embodiment 304. The method of embodiment 297, wherein said ophthalmic disease is ocular hypertension.


Embodiment 305. A method of improving vision in a subject in need thereof, said method comprising administering to said subject an active pharmaceutical ingredient and a silicone excipient.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1. Lowering intra-ocular pressure (TOP) in normotensive rabbits as a function of time.





DETAILED DESCRIPTION OF THE INVENTION
I. Definitions

The terms “a,” “an,” or “the” as used herein not only include aspects with one member, but also aspects with more than one member. For example, an embodiment including “a buffer and a chelating agent” should be understood to present aspects with at least a second buffer, at least a second chelating agent, or both.


The term “or” as used herein should in general be construed non-exclusively. For example, an embodiment of “a formulation including A or B” would typically present an aspect with a formulation including both A and B. “Or” should, however, be construed to exclude those aspects presented that cannot be combined without contradiction (e.g., a formulation pH that is between 9 and 10 or between 7 and 8).


“Agent” as used herein indicates a compound or mixture of compounds that, when added to a pharmaceutical formulation, tend to produce a particular effect on the formulation's properties. For example, a formulation including a thickening agent is likely to be more viscous than an otherwise identical comparative formulation that lacks the thickening agent.


“Formulation,” “composition,” and “preparation” as used herein are equivalent terms referring to a composition of matter suitable for pharmaceutical use (i.e., producing a therapeutic effect as well as possessing acceptable pharmacokinetic and toxicological properties).


The term “non-aqueous” composition or formulation (e.g. non-aqueous ophthalmic compositions) as provided herein refers to a composition where water is present at an amount approximately equal to or less than 20% w/w. In some embodiments, water is present at an amount less than 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, 0.001, 0.0001, 0.00001, or 0.000001% w/w. In some embodiments, water is present at an amount less than 5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, 0.001, 0.0001, 0.00001, or 0.000001% w/w. In some embodiments, water is present at an amount less than 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, 0.001, 0.0001, 0.00001, or 0.000001% w/w. In some embodiments, water is present at an amount less than 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, 0.001, 0.0001, 0.00001, or 0.000001% w/w. In some embodiments, water is present at an amount less than 1% w/w. In some embodiments, water is present at an amount less than 0.5% w/w. In some embodiments, water is present at an amount less than 0.1% w/w. In some embodiments, water is present at an amount less than 0.01% w/w. In some embodiments, water is present at an amount less than 0.001% w/w. In some embodiments, water is present at an amount less than 0.0001% w/w. In some embodiments, water is present at an amount less than 0.00001% w/w. In some embodiments, water is present at an amount less than 0.000001% w/w. In some embodiments, water is present at an amount less than 0.0000001% w/w. In some embodiments, water is present in trace amounts. In some embodiments, water is absent. In other embodiments, the non-aqueous composition includes traces of water. In other embodiments, the non-aqueous composition includes no water.


As used herein, the term “pharmaceutically” acceptable is used as equivalent to physiologically acceptable. In certain embodiments, a pharmaceutically acceptable composition or preparation will include agents for buffering and preservation in storage, and can include buffers and carriers for appropriate delivery, depending on the route of administration.


As used herein, the terms “prevent” and “treat” are not intended to be absolute terms. Treatment can refer to any delay in onset, e.g., reduction in the frequency or severity of symptoms, amelioration of symptoms, improvement in patient comfort, reduction in skin inflammation, and the like. The effect of treatment can be compared to an individual or pool of individuals not receiving a given treatment, or to the same patient before, or after cessation of, treatment.


The terms “subject,” “patient,” “individual,” and the like as used herein are not intended to be limiting and can be generally interchanged. That is, an individual described as a “patient” does not necessarily have a given disease, but may be merely seeking medical advice.


The term “subject” as used herein includes all members of the animal kingdom prone to suffering from the indicated disorder. In some aspects, the subject is a mammal, and in some aspects, the subject is a human.


The terms “effective amount,” “therapeutically effective amount” or “pharmaceutically effective amount” as used herein refers to that amount of the therapeutic agent sufficient to ameliorate one or more aspects of the disorder. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising an agent as set forth herein required to provide a clinically significant decrease in an ophthalmic disease. For example, for the given aspect (e.g., length of incidence), a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.


“Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, “treatment” as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms (e.g., ocular pain, seeing halos around lights, red eye, very high intraocular pressure), fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things.


“Treating” and “treatment” as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of an active agent. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.


The term “disease” refers to any deviation from the normal health of a mammal and includes a state when disease symptoms are present, as well as conditions in which a deviation (e.g., infection, gene mutation, genetic defect, etc.) has occurred, but symptoms are not yet manifested. According to the present invention, the methods disclosed herein are suitable for use in a patient that is a member of the Vertebrate class, Mammalia, including, without limitation, primates, livestock and domestic pets (e.g., a companion animal). Typically, a patient will be a human patient.


As used herein, “topical application,” “topical administration,” and “topically administering” are used interchangeably herein and include the administration of a composition to the eye, the mucosal or dermal area proximal to the eye. Topical application or administering may result in the delivery of an active agent to the eye or skin, a localized region of the body, a localized volume of the body, or the systemic circulation.


“Topical formulation” and “topical pharmaceutical composition” are used interchangeably herein and include a formulation that is suitable for topical application to the eye or dermal area proximal to the eye, or other localized region of the body. A topical formulation may, for example, be used to confer a therapeutic benefit to its user. Specific topical formulations can be used for topical, local, regional, or transdermal application of substances.


As used herein, the terms “application,” “apply,” and “applying” used in reference to a topical composition product or method of using a composition or a product, refer to any manner of administering a topical composition or a product to the eye, the mucosal or dermal area proximal to the eye of a patient which, in medical or cosmetology practice, delivers the composition or the product to patient's eye, the mucosal or dermal area proximal to the eye. Smearing, rubbing, spreading, spraying a topical composition, with or without the aid of suitable devices, on a patient's skin are all included within the scope of the term “application,” as used herein. The term “topical” or “topically” in reference to administration or application of a composition or a product refers to epicuatenous administration or application, or administration onto skin. The term “topically active agent” as used herein refers to a compound that is effective in a treatment of a skin condition when administered topically. It is to be understood that topically active agent can have a local or a systemic effect, or both, when administered topically. The term “topical,” when used in reference to a composition or a product refers to a composition or a product formulated for topical application.


The abbreviations used herein have their conventional meaning within the chemical, biological or pharmaceutical arts.


The terms “about” and “approximately equal” are used herein to modify a numerical value and indicate a defined range around that value. If “X” were the value, “about X” or “approximately equal to X” would generally indicate a value from 0.90× to 1.10×. Any reference to “about X” minimally indicates at least the values X, 0.90X, 0.91X, 0.92X, 0.93X, 0.94X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, and 1.10X. Thus, “about X” is intended to disclose, e.g., “0.98×.” When “about” is applied to the beginning of a numerical range, it applies to both ends of the range. Thus, “from about 6 to 8.5” is equivalent to “from about 6 to about 8.5.” When “about” is applied to the first value of a set of values, it applies to all values in that set. Thus, “about 7, 9, or 11%” is equivalent to “about 7%, about 9%, or about 11%.”


As used herein, the phrase “pharmaceutically acceptable salts” refers to salts of the active compound(s) which possess the same pharmacological activity as the active compound(s) and which are neither biologically nor otherwise undesirable. A salt can be formed with, for example, organic or inorganic acids. Non-limiting examples of suitable acids include acetic acid, acetylsalicylic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, bisulfic acid, boric acid, butyric acid, camphoric acid, camphorsulfonic acid, carbonic acid, citric acid, cyclopentanepropionic acid, digluconic acid, dodecylsulfic acid, ethanesulfonic acid, formic acid, fumaric acid, glyceric acid, glycerophosphoric acid, glycine, glucoheptanoic acid, gluconic acid, glutamic acid, glutaric acid, glycolic acid, hemisulfic acid, heptanoic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthylanesulfonic acid, naphthylic acid, nicotinic acid, nitrous acid, oxalic acid, pelargonic, phosphoric acid, propionic acid, saccharin, salicylic acid, sorbic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, thioglycolic acid, thiosulfuric acid, tosylic acid, undecylenic acid, naturally and synthetically derived amino acids. Non-limiting examples of base salts include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts; methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; asthma halides, such as benzyl and phenethyl bromides; and others.


In formulations including an “additional,” “further,” or “second” component, the second component as used herein is chemically different from the other components or first component. A “third” component is different from the other, first, and second components, and further enumerated or “additional” components are similarly different.


The term “hydrophobic” is used herein in accordance with its plain ordinary meaning and refers to a chemical group having a tendency to attract non-polar or uncharged chemical groups, e.g. hexane, and to repel polar or charged chemical groups, e.g. water.


The term “hydrophilic” is used herein in accordance with its plain ordinary meaning and refers to a chemical group having a tendency to repel non-polar or uncharged chemical groups, e.g. hexane, and to attract polar or charged chemical groups, e.g. water.


II. Compositions

The present invention provides aqueous and non-aqueous pharmaceutical compositions including a pharmaceutically active ingredient (e.g. multiple pharmaceutically active ingredients) and a silicone excipient. In some embodiments, the silicone excipient is a silicone excipient blend. The pharmaceutical composition may have multiple silicone excipient blends. The silicone based pharmaceutical compositions provided herein may be used for the treatment of ophthalmic diseases. Ointments, creams, gels, sprays, stick formulations, and emulsions are contemplated as useful pharmaceutical formulations including the compositions provided herein.


In one aspect, a composition including an active pharmaceutical ingredient (also referred to herein as an “active ingredient”) and a silicone excipient is provided. In some embodiments, the composition is an ophthalmic pharmaceutical formulation (i.e. a pharmaceutical formulation suitable for use ophthalmically and having ophthalmically acceptable excipients). The active pharmaceutical ingredients are present in an amount effective to treat ophthalmic diseases.


The compositions provided herein may include an immunosuppressant, a vasodilator agent, an anti-inflammatory agent, an EP2 receptor agonist, a muscarinic receptor agonist, a prostaglandin analog, a vasoconstrictor agent, or an anti-infective agent as active pharmaceutical ingredients. In some embodiments, the composition provided herein includes an immunosuppressant (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes an vasodilator agent (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes an anti-inflammatory agent (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes an EP2 receptor agonist (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes a muscarinic receptor agonist (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes a prostaglandin analog (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes a vasoconstrictor agent (e.g. in the absence of another active ingredient). In some embodiments, the composition provided herein includes an anti-infective agent (e.g. in the absence of another active ingredient). It is also to be understood that pharmaceutically acceptable salts of the active pharmaceutical ingredients may be included in the compositions provided herein.


In some embodiments, the active pharmaceutical ingredient is an immunosuppressant. An immunosuppressant as defined herein is an agent that can suppress or prevent the immune response. Immunosuppressants are generally used when a normal immune response is undesirable (e.g. organ transplantation, autoimmune diseases). Examples of immunosuppressants suitable for the compositions and methods according to the embodiments of the present invention are TNF-α inhibitors including thalidomide and lenalidomide; IL-2 inhibitors including abetimus and gusperimus; macrolides including cyclosporine and tacrolimus; purine and pyrimidine synthesis inhibitors including azathioprine, mycophenolic acid, leflunomide and teriflunomide. In some further embodiment, the immunosuppressant is cyclosporine. In some embodiments, the cyclosporine is cyclosporine A. In other embodiments, the immunosuppressant is any appropriate pharmaceutical salt, prodrug and/or analog of cyclosporine. In some embodiments, the cyclosporine is present in an amount approximately equal to or less than about 4% w/w. In some embodiments, the cyclosporine is present from about 0.0001 to about 4, from about 0.0005 to about 4, from about 0.001 to about 4, from about 0.005 to about 4, from about 0.01 to about 4, from about 0.02 to about 4, from about 0.04 to about 4, from about 0.06 to about 4, from about 0.08 to about 4, from about 0.1 to about 4, from about 0.2 to about 4, from about 0.4 to about 4, from about 0.6 to about 4, from about 0.8 to about 4, from about 1 to about 4, from about 2 to about 4, from about 3 to about 4, from about 0.0001 to about 3, from about 0.0005 to about 3, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.02 to about 3, from about 0.04 to about 3, from about 0.06 to about 3, from about 0.08 to about 3, from about 0.1 to about 3, from about 0.2 to about 3, from about 0.4 to about 3, from about 0.6 to about 3, from about 0.8 to about 3, from about 1 to about 3, from about 2 to about 3, from about 0.0001 to about 2, from about 0.0005 to about 2, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.02 to about 2, from about 0.04 to about 2, from about 0.06 to about 2, from about 0.08 to about 2, from about 0.1 to about 2, from about 0.2 to about 2, from about 0.4 to about 2, from about 0.6 to about 2, from about 0.8 to about 2, from about 1 to about 2, from about 0.0001 to about 1, from about 0.0005 to about 1, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.02 to about 1, from about 0.04 to about 1, from about 0.06 to about 1, from about 0.08 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.4 to about 1, from about 0.6 to about 1, or from about 0.8 to about 1% (w/w). The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the cyclosporine is present from about 0.0001 to about 0.8, from about 0.0005 to about 0.8, from about 0.001 to about 0.8, from about 0.005 to about 0.8, from about 0.01 to about 0.8, from about 0.02 to about 0.8, from about 0.04 to about 0.8, from about 0.06 to about 0.8, from about 0.08 to about 0.8, from about 0.1 to about 0.8, from about 0.2 to about 0.8, from about 0.4 to about 0.8, from about 0.6 to about 0.8, from about 0.0001 to about 0.6, from about 0.0005 to about 0.6, from about 0.001 to about 0.6, from about 0.005 to about 0.6, from about 0.01 to about 0.6, from about 0.02 to about 0.6, from about 0.04 to about 0.6, from about 0.06 to about 0.6, from about 0.08 to about 0.6, from about 0.1 to about 0.6, from about 0.2 to about 0.6, from about 0.4 to about 0.6, from about 0.0001 to about 0.4, from about 0.0005 to about 0.4, from about 0.001 to about 0.4, from about 0.005 to about 0.4, from about 0.01 to about 0.4, from about 0.02 to about 0.4, from about 0.04 to about 0.4, from about 0.06 to about 0.4, from about 0.08 to about 0.4, from about 0.1 to about 0.4, from about 0.2 to about 0.4, from about 0.0001 to about 0.2, from about 0.0005 to about 0.2, from about 0.001 to about 0.2, from about 0.005 to about 0.2, from about 0.01 to about 0.2, from about 0.02 to about 0.2, from about 0.04 to about 0.2, from about 0.06 to about 0.2, from about 0.08 to about 0.2, or from about 0.1 to about 0.2% (w/w). The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the cyclosporine is present from about 0.0001 to about 0.1, from about 0.0005 to about 0.1, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.04 to about 0.1, from about 0.06 to about 0.1, from about 0.08 to about 0.1, from about 0.0001 to about 0.08, from about 0.0005 to about 0.08, from about 0.001 to about 0.08, from about 0.005 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.04 to about 0.08, from about 0.06 to about 0.08, from about 0.0001 to about 0.06, from about 0.0005 to about 0.06, from about 0.001 to about 0.06, from about 0.005 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.04 to about 0.06, from about 0.0001 to about 0.04, from about 0.0005 to about 0.04, from about 0.001 to about 0.04, from about 0.005 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.0001 to about 0.02, from about 0.0005 to about 0.02, from about 0.001 to about 0.02, from about 0.005 to about 0.02, from about 0.01 to about 0.02, from about 0.0001 to about 0.01, from about 0.0005 to about 0.01, from about 0.001 to about 0.01, from about 0.005 to about 0.01, from about 0.0001 to about 0.005, from about 0.0005 to about 0.005, from about 0.001 to about 0.005, from about 0.0001 to about 0.001, from about 0.0005 to about 0.001, or from about 0.0001 to about 0.0005% (w/w). In some embodiments, the cyclosporine is present at about 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, or 4% (w/w). In some embodiments, the cyclosporine is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the immunosuppressant is tacrolimus. In other embodiments, the immunosuppressant is any appropriate pharmaceutical salt, prodrug and/or analog of tacrolimus. In some embodiments, the tacrolimus is present in an amount approximately equal to or less than about 0.1% w/w. In some embodiments, the tacrolimus is present from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.02 to about 0.09, from about 0.03 to about 0.09, from about 0.04 to about 0.09, from about 0.05 to about 0.09, from about 0.06 to about 0.09, from about 0.07 to about 0.09, from about 0.08 to about 0.09, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, from about 0.07 to about 0.08, from about 0.02 to about 0.07, from about 0.03 to about 0.07, from about 0.04 to about 0.07, from about 0.05 to about 0.07, from about 0.06 to about 0.07, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.02 to about 0.05, from about 0.03 to about 0.05, from about 0.04 to about 0.05, from about 0.02 to about 0.04, from about 0.03 to about 0.04, or from about 0.02 to about 0.03% (w/w). In some embodiments, the tacrolimus is present at about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% (w/w). In some embodiments, the tacrolimus is present in an amount of about 0.01% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the active pharmaceutical ingredient is a vasodilator agent. A vasodilator agent as defined herein is an agent that widens the blood vessels, which in turn decreases resistance to blood flow and lowers blood pressure. Based on their mechanism of action vasodilators (i.e. vasodilator agents) can be calcium channel blockers or alpha adrenergic antagonists. Examples of calcium channel blockers are amlodipine, felodipine, isradipine, lecranidipine, nicardipine, nifedipine, nimodipine, diltiazem and verapamil. Examples of adrenergic antagonists are doxazosin, phentolamine, phenoxybenzamine, terazosin, tolazoline, and idazoxan. In some embodiments, the vasodilator agent is an alpha adrenergic antagonist. In some further embodiments, the alpha adrenergic antagonist is phentolamine. In other embodiments, the alpha adrenergic antagonist is any appropriate pharmaceutical salt, prodrug and/or analog of phentolamine 1n some embodiments, the phentolamine is present in an amount approximately equal to or less than about 4% w/w. In some embodiments, the phentolamine is present from about 0.0001 to about 4, from about 0.0005 to about 4, from about 0.001 to about 4, from about 0.005 to about 4, from about 0.01 to about 4, from about 0.02 to about 4, from about 0.04 to about 4, from about 0.06 to about 4, from about 0.08 to about 4, from about 0.1 to about 4, from about 0.2 to about 4, from about 0.4 to about 4, from about 0.6 to about 4, from about 0.8 to about 4, from about 1 to about 4, from about 2 to about 4, from about 3 to about 4, from about 0.0001 to about 3, from about 0.0005 to about 3, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.02 to about 3, from about 0.04 to about 3, from about 0.06 to about 3, from about 0.08 to about 3, from about 0.1 to about 3, from about 0.2 to about 3, from about 0.4 to about 3, from about 0.6 to about 3, from about 0.8 to about 3, from about 1 to about 3, from about 2 to about 3, from about 0.0001 to about 2, from about 0.0005 to about 2, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.02 to about 2, from about 0.04 to about 2, from about 0.06 to about 2, from about 0.08 to about 2, from about 0.1 to about 2, from about 0.2 to about 2, from about 0.4 to about 2, from about 0.6 to about 2, from about 0.8 to about 2, from about 1 to about 2, from about 0.0001 to about 1, from about 0.0005 to about 1, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.02 to about 1, from about 0.04 to about 1, from about 0.06 to about 1, from about 0.08 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.4 to about 1, from about 0.6 to about 1, or from about 0.8 to about 1% (w/w). The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the phentolamine is present from about 0.0001 to about 0.8, from about 0.0005 to about 0.8, from about 0.001 to about 0.8, from about 0.005 to about 0.8, from about 0.01 to about 0.8, from about 0.02 to about 0.8, from about 0.04 to about 0.8, from about 0.06 to about 0.8, from about 0.08 to about 0.8, from about 0.1 to about 0.8, from about 0.2 to about 0.8, from about 0.4 to about 0.8, from about 0.6 to about 0.8, from about 0.0001 to about 0.6, from about 0.0005 to about 0.6, from about 0.001 to about 0.6, from about 0.005 to about 0.6, from about 0.01 to about 0.6, from about 0.02 to about 0.6, from about 0.04 to about 0.6, from about 0.06 to about 0.6, from about 0.08 to about 0.6, from about 0.1 to about 0.6, from about 0.2 to about 0.6, from about 0.4 to about 0.6, from about 0.0001 to about 0.4, from about 0.0005 to about 0.4, from about 0.001 to about 0.4, from about 0.005 to about 0.4, from about 0.01 to about 0.4, from about 0.02 to about 0.4, from about 0.04 to about 0.4, from about 0.06 to about 0.4, from about 0.08 to about 0.4, from about 0.1 to about 0.4, from about 0.2 to about 0.4, from about 0.0001 to about 0.2, from about 0.0005 to about 0.2, from about 0.001 to about 0.2, from about 0.005 to about 0.2, from about 0.01 to about 0.2, from about 0.02 to about 0.2, from about 0.04 to about 0.2, from about 0.06 to about 0.2, from about 0.08 to about 0.2, or from about 0.1 to about 0.2% (w/w). The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the phentolamine is present from about 0.0001 to about 0.1, from about 0.0005 to about 0.1, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.04 to about 0.1, from about 0.06 to about 0.1, from about 0.08 to about 0.1, from about 0.0001 to about 0.08, from about 0.0005 to about 0.08, from about 0.001 to about 0.08, from about 0.005 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.04 to about 0.08, from about 0.06 to about 0.08, from about 0.0001 to about 0.06, from about 0.0005 to about 0.06, from about 0.001 to about 0.06, from about 0.005 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.04 to about 0.06, from about 0.0001 to about 0.04, from about 0.0005 to about 0.04, from about 0.001 to about 0.04, from about 0.005 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.0001 to about 0.02, from about 0.0005 to about 0.02, from about 0.001 to about 0.02, from about 0.005 to about 0.02, from about 0.01 to about 0.02, from about 0.0001 to about 0.01, from about 0.0005 to about 0.01, from about 0.001 to about 0.01, from about 0.005 to about 0.01, from about 0.0001 to about 0.005, from about 0.0005 to about 0.005, from about 0.001 to about 0.005, from about 0.0001 to about 0.001, from about 0.0005 to about 0.001, or from about 0.0001 to about 0.0005% (w/w). In some embodiments, the phentolamine is present at about 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, or 4% (w/w). In some embodiments, the phentolamine is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the active pharmaceutical ingredient is an anti-inflammatory agent. Anti-inflammatory agents as defined herein are agents capable of reducing inflammation. Anti-inflammatory agents include steroids (e.g. glucocorticoids, androgens), non-steroidal anti-inflammatory agent (e.g. non-steroidal anti-inflammatory drugs (NSAID)) and immune selective anti-inflammatory derivatives (ImSAIDs). In some embodiments, the anti-inflammatory agent is a non-steroidal anti-inflammatory agent. Non-steroidal anti-inflammatory agents include drugs with analgesic and fever-reducing effects, which inhibit the synthesis of prostaglandins. Examples of non-steroidal anti-inflammatory agents include aspirin, ibuprofen, naproxen, etodolac, ketorolac, tenoxicam, lornoxicam, celecoxib, and nemesolide. In some embodiments, the non-steroidal anti-inflammatory agent is ketorolac. In other embodiments, the non-steroidal anti-inflammatory agent is any appropriate pharmaceutical salt, prodrug and/or analog of ketorolac. In some embodiments, the ketorolac is present in an amount approximately equal to or less than about 2% w/w. In some embodiments, the ketorolac is present from about 0.001 to about 2, from about 0.004 to about 2, from about 0.008 to about 2, from about 0.01 to about 2, from about 0.04 to about 2, from about 0.08 to about 2, from about 0.1 to about 2, from about 0.4 to about 2, from about 0.8 to about 2, from about 1 to about 2, from about 1.4 to about 2, from about 1.8 to about 2, from about 0.001 to about 1.8, from about 0.004 to about 1.8, from about 0.008 to about 1.8, from about 0.01 to about 1.8, from about 0.04 to about 1.8, from about 0.08 to about 1.8, from about 0.1 to about 1.8, from about 0.4 to about 1.8, from about 0.8 to about 1.8, from about 1 to about 1.8, or from about 1.4 to about 1.8% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the ketorolac is present from about 0.001 to about 1.4, from about 0.004 to about 1.4, from about 0.008 to about 1.4, from about 0.01 to about 1.4, from about 0.04 to about 1.4, from about 0.08 to about 1.4, from about 0.1 to about 1.4, from about 0.4 to about 1.4, from about 0.8 to about 1.4, from about 1 to about 1.4, from about 0.001 to about 1, from about 0.004 to about 1, from about 0.008 to about 1, from about 0.01 to about 1, from about 0.04 to about 1, from about 0.08 to about 1, from about 0.1 to about 1, from about 0.4 to about 1, from about 0.8 to about 1, from about 0.001 to about 0.8, from about 0.004 to about 0.8, from about 0.008 to about 0.8, from about 0.01 to about 0.8, from about 0.04 to about 0.8, from about 0.08 to about 0.8, from about 0.1 to about 0.8, from about 0.4 to about 0.8, from about 0.001 to about 0.4, from about 0.004 to about 0.4, from about 0.008 to about 0.4, from about 0.01 to about 0.4, from about 0.04 to about 0.4, from about 0.08 to about 0.4, from about 0.1 to about 0.4, from about 0.001 to about 0.1, from about 0.004 to about 0.1, from about 0.008 to about 0.1, from about 0.01 to about 0.1, from about 0.04 to about 0.1, from about 0.08 to about 0.1, from about 0.001 to about 0.08, from about 0.004 to about 0.08, from about 0.008 to about 0.08, from about 0.01 to about 0.08, from about 0.04 to about 0.08, from about 0.001 to about 0.04, from about 0.004 to about 0.04, from about 0.008 to about 0.04, from about 0.01 to about 0.04, from about 0.001 to about 0.01, from about 0.004 to about 0.01, from about 0.008 to about 0.01, from about 0.001 to about 0.008, from about 0.004 to about 0.008, or from about 0.001 to about 0.0045w/w. In some embodiments, the ketorolac is present at about 0.001, 0.004, 0.008, 0.01, 0.04, 0.08, 0.1, 0.4, 0.8, 1, 1.4, 1.8 or 2% (w/w). In some embodiments, the ketorolac is present in an amount of about 0.01% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the anti-inflammatory agent is an androgen. Androgens are steroid hormones that stimulate or control the development and maintenance of male characteristics in vertebrates by binding to androgen receptors. Androgens are produced naturally by the testis and are required for the activity of the accessory male sex organs and the development of male secondary sex characteristics. Examples of androgens include testosterone, dihydrotestosterone, dehydroepiandrosterone, androsterone and androstenedione. In some further embodiments, the anti-inflammatory agent is testosterone. In other embodiments, the anti-inflammatory agent is any appropriate pharmaceutical salt, prodrug and/or analog of testosterone. In some embodiments, the testosterone is present in an amount approximately equal to or less than about 5% w/w. In some embodiments, the testosterone is present from about 0.001 to about 5, from about 0.005 to about 5, from about 0.01 to about 5, from about 0.05 to about 5, from about 0.1 to about 5, from about 0.5 to about 5, from about 1 to about 5, from about 1.5 to about 5, from about 2 to about 5, from about 2.5 to about 5, from about 3 to about 5, from about 3.5 to about 5, from about 4 to about 5, from about 4.5, from about 0.001 to about 4.5, from about 0.005 to about 4.5, from about 0.01 to about 4.5, from about 0.05 to about 4.5, from about 0.1 to about 4.5, from about 0.5 to about 4.5, from about 1 to about 4.5, from about 1.5 to about 4.5, from about 2 to about 4.5, from about 2.5 to about 4.5, from about 3 to about 4.5, from about 3.5 to about 4.5, from about 4 to about 4.5, from about 0.001 to about 4, from about 0.005 to about 4, or from about 0.01 to about 4% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the testosterone is present from about 0.05 to about 4, from about 0.1 to about 4, from about 0.5 to about 4, from about 1 to about 4, from about 1.5 to about 4, from about 2 to about 4, from about 2.5 to about 4, from about 3 to about 4, from about 3.5 to about 4, from about 0.001 to about 3.5, from about 0.005 to about 3.5, from about 0.01 to about 3.5, from about 0.05 to about 3.5, from about 0.1 to about 3.5, from about 0.5 to about 3.5, from about 1 to about 3.5, from about 1.5 to about 3.5, from about 2 to about 3.5, from about 2.5 to about 3.5, from about 3 to about 3.5, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.001 to about 2.5, from about 0.005 to about 2.5, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.001 to about 1.5, from about 0.005 to about 1.5, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.001 to about 0.5, from about 0.005 to about 0.5, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.05 to about 0.1, from about 0.001 to about 0.05, from about 0.005 to about 0.05, from about 0.01 to about 0.05, or from about 0.001 to about 0.005% (w/w). In some embodiments, the testosterone is present at about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% (w/w). In some embodiments, the testosterone is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the anti-inflammatory agent is dihydrotestosterone. In other embodiments, the anti-inflammatory agent is any appropriate pharmaceutical salt, prodrug and/or analog of dihydrotestosterone. In some embodiments, the dihydrotestosterone is present in an amount approximately equal to or less than about 5% w/w. In some embodiments, the dihydrotestosterone is present from about 0.001 to about 5, from about 0.005 to about 5, from about 0.01 to about 5, from about 0.05 to about 5, from about 0.1 to about 5, from about 0.5 to about 5, from about 1 to about 5, from about 1.5 to about 5, from about 2 to about 5, from about 2.5 to about 5, from about 3 to about 5, from about 3.5 to about 5, from about 4 to about 5, from about 4.5, from about 0.001 to about 4.5, from about 0.005 to about 4.5, from about 0.01 to about 4.5, from about 0.05 to about 4.5, from about 0.1 to about 4.5, from about 0.5 to about 4.5, from about 1 to about 4.5, from about 1.5 to about 4.5, from about 2 to about 4.5, from about 2.5 to about 4.5, from about 3 to about 4.5, from about 3.5 to about 4.5, or from about 4 to about 4.5% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the dihydrotestosterone is present from about 0.001 to about 4, from about 0.005 to about 4, from about 0.01 to about 4, from about 0.05 to about 4, from about 0.1 to about 4, from about 0.5 to about 4, from about 1 to about 4, from about 1.5 to about 4, from about 2 to about 4, from about 2.5 to about 4, from about 3 to about 4, from about 3.5 to about 4, from about 0.001 to about 3.5, from about 0.005 to about 3.5, from about 0.01 to about 3.5, from about 0.05 to about 3.5, from about 0.1 to about 3.5, from about 0.5 to about 3.5, from about 1 to about 3.5, from about 1.5 to about 3.5, from about 2 to about 3.5, from about 2.5 to about 3.5, from about 3 to about 3.5, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.001 to about 2.5, from about 0.005 to about 2.5, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.001 to about 1.5, from about 0.005 to about 1.5, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.001 to about 0.5, from about 0.005 to about 0.5, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.05 to about 0.1, from about 0.001 to about 0.05, from about 0.005 to about 0.05, from about 0.01 to about 0.05, or from about 0.001 to about 0.005% (w/w). In some embodiments, the dihydrotestosterone is present at about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% (w/w). In some embodiments, the dihydrotestosterone is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the anti-inflammatory agent is testosterone propionate. In other embodiments, the anti-inflammatory agent is any appropriate pharmaceutical salt, prodrug and/or analog of testosterone propionate. In some embodiments, the testosterone propionate is present in an amount approximately equal to or less than about 5% w/w. In some embodiments, the testosterone propionate is present from about 0.001 to about 5, from about 0.005 to about 5, from about 0.01 to about 5, from about 0.05 to about 5, from about 0.1 to about 5, from about 0.5 to about 5, from about 1 to about 5, from about 1.5 to about 5, from about 2 to about 5, from about 2.5 to about 5, from about 3 to about 5, from about 3.5 to about 5, from about 4 to about 5, from about 4.5, from about 0.001 to about 4.5, from about 0.005 to about 4.5, from about 0.01 to about 4.5, from about 0.05 to about 4.5, from about 0.1 to about 4.5, from about 0.5 to about 4.5, from about 1 to about 4.5, from about 1.5 to about 4.5, from about 2 to about 4.5, from about 2.5 to about 4.5, from about 3 to about 4.5, from about 3.5 to about 4.5, from about 4 to about 4.5, from about 0.001 to about 4, from about 0.005 to about 4, from about 0.01 to about 4, from about 0.05 to about 4, from about 0.1 to about 4, from about 0.5 to about 4, from about 1 to about 4, from about 1.5 to about 4, from about 2 to about 4, from about 2.5 to about 4, from about 3 to about 4, from about 3.5 to about 4% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the testosterone propionate is present from about 0.001 to about 3.5, from about 0.005 to about 3.5, from about 0.01 to about 3.5, from about 0.05 to about 3.5, from about 0.1 to about 3.5, from about 0.5 to about 3.5, from about 1 to about 3.5, from about 1.5 to about 3.5, from about 2 to about 3.5, from about 2.5 to about 3.5, from about 3 to about 3.5, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.001 to about 2.5, from about 0.005 to about 2.5, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.001 to about 1.5, from about 0.005 to about 1.5, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.001 to about 0.5, from about 0.005 to about 0.5, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.05 to about 0.1, from about 0.001 to about 0.05, from about 0.005 to about 0.05, from about 0.01 to about 0.05, or from about 0.001 to about 0.005% (w/w). In some embodiments, the testosterone propionate is present at about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% (w/w). In some embodiments, the testosterone propionate is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


The anti-inflammatory agent provided herein may be dexamethasone or prednisolone. In some embodiments, the anti-inflammatory agent is dexamethasone. In other embodiments, the anti-inflammatory agent is any appropriate pharmaceutical salt, prodrug and/or analog of dexamethasone. In some embodiments, the dexamethasone is present in an amount approximately equal to or less than about 5% w/w. In some embodiments, the dexamethasone is present from about 0.001 to about 5, from about 0.005 to about 5, from about 0.01 to about 5, from about 0.05 to about 5, from about 0.1 to about 5, from about 0.5 to about 5, from about 1 to about 5, from about 1.5 to about 5, from about 2 to about 5, from about 2.5 to about 5, from about 3 to about 5, from about 3.5 to about 5, from about 4 to about 5, from about 4.5, from about 0.001 to about 4.5, from about 0.005 to about 4.5, from about 0.01 to about 4.5, from about 0.05 to about 4.5, from about 0.1 to about 4.5, from about 0.5 to about 4.5, from about 1 to about 4.5, from about 1.5 to about 4.5, from about 2 to about 4.5, from about 2.5 to about 4.5, from about 3 to about 4.5, from about 3.5 to about 4.5, from about 4 to about 4.5, from about 0.001 to about 4, from about 0.005 to about 4, from about 0.01 to about 4, from about 0.05 to about 4, from about 0.1 to about 4, from about 0.5 to about 4, from about 1 to about 4, from about 1.5 to about 4, from about 2 to about 4, from about 2.5 to about 4, from about 3 to about 4, from about 3.5 to about 4, from about 0.001 to about 3.5, from about 0.005 to about 3.5, from about 0.01 to about 3.5, from about 0.05 to about 3.5, from about 0.1 to about 3.5, from about 0.5 to about 3.5, from about 1 to about 3.5, from about 1.5 to about 3.5, from about 2 to about 3.5, from about 2.5 to about 3.5, from about 3 to about 3.5, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.001 to about 2.5, from about 0.005 to about 2.5, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.001 to about 1.5, from about 0.005 to about 1.5, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.001 to about 0.5, from about 0.005 to about 0.5, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.05 to about 0.1, from about 0.001 to about 0.05, from about 0.005 to about 0.05, from about 0.01 to about 0.05, or from about 0.001 to about 0.005% (w/w). In some embodiments, the dexamethasone is present at about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% (w/w). In some embodiments, the dexamethasone is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In other embodiments, the anti-inflammatory agent is prednisolone. In other embodiments, the anti-inflammatory agent is any appropriate pharmaceutical salt, prodrug and/or analog of prednisolone. In some embodiments, the prednisolone is present in an amount approximately equal to or less than about 5% w/w. In some embodiments, the prednisolone is present from about 0.001 to about 5, from about 0.005 to about 5, from about 0.01 to about 5, from about 0.05 to about 5, from about 0.1 to about 5, from about 0.5 to about 5, from about 1 to about 5, from about 1.5 to about 5, from about 2 to about 5, from about 2.5 to about 5, from about 3 to about 5, from about 3.5 to about 5, from about 4 to about 5, from about 4.5, from about 0.001 to about 4.5, from about 0.005 to about 4.5, from about 0.01 to about 4.5, from about 0.05 to about 4.5, from about 0.1 to about 4.5, from about 0.5 to about 4.5, from about 1 to about 4.5, from about 1.5 to about 4.5, from about 2 to about 4.5, from about 2.5 to about 4.5, from about 3 to about 4.5, from about 3.5 to about 4.5, from about 4 to about 4.5, from about 0.001 to about 4, from about 0.005 to about 4, from about 0.01 to about 4, from about 0.05 to about 4, from about 0.1 to about 4, from about 0.5 to about 4, from about 1 to about 4, from about 1.5 to about 4, from about 2 to about 4, from about 2.5 to about 4, from about 3 to about 4, from about 3.5 to about 4, from about 0.001 to about 3.5, from about 0.005 to about 3.5, from about 0.01 to about 3.5, from about 0.05 to about 3.5, from about 0.1 to about 3.5, from about 0.5 to about 3.5, from about 1 to about 3.5, from about 1.5 to about 3.5, from about 2 to about 3.5, from about 2.5 to about 3.5, from about 3 to about 3.5, from about 0.001 to about 3, from about 0.005 to about 3, from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.001 to about 2.5, from about 0.005 to about 2.5, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.001 to about 2, from about 0.005 to about 2, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.001 to about 1.5, from about 0.005 to about 1.5, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.001 to about 1, from about 0.005 to about 1, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.001 to about 0.5, from about 0.005 to about 0.5, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.001 to about 0.1, from about 0.005 to about 0.1, from about 0.01 to about 0.1, from about 0.05 to about 0.1, from about 0.001 to about 0.05, from about 0.005 to about 0.05, from about 0.01 to about 0.05, or from about 0.001 to about 0.005% (w/w). In some embodiments, the prednisolone is present at about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% (w/w). In some embodiments, the prednisolone is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the composition provided herein includes an EP2 receptor agonist. An EP2 receptor agonist is an agent capable of binding a prostaglandin E2 receptor. EP2 receptor agonists typically increase an activity of a prostaglandin E2 receptor. A prostaglandin E2 receptor as used herein according to the ordinary usage in the art, and generally refers to a G-protein coupled receptor that may be bound by prostaglandin E2. Prostaglandin E2 is used according to its ordinary meaning and generally refers to a lipid mediator that is derived enzymatically from fatty acids. E2 prostaglandins may have a variety of strong physiological effects, such as regulating the contraction and relaxation of smooth muscle tissue. Agents capable of binding a prostaglandin E2 receptor are referred to herein as EP2 receptor agonists. Non limiting examples of EP2 receptor agonists are small molecules and chemical compounds. The compositions provided herein may include one or more EP2 receptor agonists. In some embodiments, the active pharmaceutical ingredient is an EP2 receptor agonist. In some embodiments, the EP2 receptor agonist is a compound of Formula




embedded image


embedded image


In some embodiments, the EP2 receptor agonist is a compound of Formula




embedded image


In other embodiments, the EP2 receptors agonist is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of Formula (Ia). In some further embodiments, the EP2 receptor agonist is present in an amount approximately equal to or less than about 0.1% w/w. In some further embodiments, the EP2 receptor agonist is present from about 0.001 to about 0.1, from about 0.002 to about 0.1, from about 0.003 to about 0.1, from about 0.004 to about 0.1, from about 0.005 to about 0.1, from about 0.006 to about 0.1, from about 0.007 to about 0.1, from about 0.008 to about 0.1, from about 0.009 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.001 to about 0.08, from about 0.002 to about 0.08, from about 0.003 to about 0.08, from about 0.004 to about 0.08, from about 0.005 to about 0.08, from about 0.006 to about 0.08, from about 0.007 to about 0.08, from about 0.008 to about 0.08, from about 0.009 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, from about 0.07 to about 0.08, from about 0.001 to about 0.06, from about 0.002 to about 0.06, from about 0.003 to about 0.06, from about 0.004 to about 0.06, from about 0.005 to about 0.06, from about 0.006 to about 0.06, from about 0.007 to about 0.06, from about 0.008 to about 0.06, from about 0.009 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.003 to about 0.04, from about 0.004 to about 0.04, from about 0.005 to about 0.04, from about 0.006 to about 0.04, from about 0.007 to about 0.04, from about 0.008 to about 0.04, from about 0.009 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.003 to about 0.02, from about 0.004 to about 0.02, from about 0.005 to about 0.02, from about 0.006 to about 0.02, from about 0.007 to about 0.02, from about 0.008 to about 0.02, from about 0.009 to about 0.02, from about 0.01 to about 0.02, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.003 to about 0.01, from about 0.004 to about 0.01, from about 0.005 to about 0.01, from about 0.006 to about 0.01, from about 0.007 to about 0.01, from about 0.008 to about 0.01, or from about 0.009 to about 0.01% (w/w). In some further embodiments, the EP2 receptor agonist is present at about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% (w/w). In some further embodiments, the EP2 receptor agonist is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the EP2 receptor agonist is a compound of Formula




embedded image


In other embodiments, the EP2 receptors agonist is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of Formula (IIa). In some further embodiment, the EP2 receptor is present in an amount approximately equal to or less than about 0.05% w/w. In some further embodiments, the EP2 receptor agonist is present from about 0.0002 to about 0.05, from about 0.0004 to about 0.05, from about 0.0006 to about 0.05, from about 0.0008 to about 0.05, from about 0.001 to about 0.05, from about 0.002 to about 0.05, from about 0.004 to about 0.05, from about 0.006 to about 0.05, from about 0.008 to about 0.05, from about 0.01 to about 0.05, from about 0.02 to about 0.05, from about 0.03 to about 0.05, from about 0.03 to about 0.05, from about 0.0002 to about 0.04, from about 0.0004 to about 0.04, from about 0.0006 to about 0.04, from about 0.0008 to about 0.04, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.004 to about 0.04, from about 0.006 to about 0.04, from about 0.008 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.0002 to about 0.03, from about 0.0004 to about 0.03, from about 0.0006 to about 0.03, from about 0.0008 to about 0.03, from about 0.001 to about 0.03, from about 0.002 to about 0.03, from about 0.004 to about 0.03, from about 0.006 to about 0.03, from about 0.008 to about 0.03, from about 0.01 to about 0.03, from about 0.02 to about 0.03, from about 0.0002 to about 0.02, from about 0.0004 to about 0.02, from about 0.0006 to about 0.02, from about 0.0008 to about 0.02, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.004 to about 0.02, from about 0.006 to about 0.02, from about 0.008 to about 0.02, from about 0.01 to about 0.02, from about 0.0002 to about 0.01, from about 0.0004 to about 0.01, from about 0.0006 to about 0.01, from about 0.0008 to about 0.01, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.004 to about 0.01, from about 0.006 to about 0.01, from about 0.008 to about 0.01, from about 0.0002 to about 0.008, from about 0.0004 to about 0.008, from about 0.0006 to about 0.008, from about 0.0008 to about 0.008, from about 0.001 to about 0.008, from about 0.002 to about 0.008, from about 0.004 to about 0.008, from about 0.006 to about 0.008, from about 0.0002 to about 0.006, from about 0.0004 to about 0.006, from about 0.001 to about 0.006, from about 0.002 to about 0.006, from about 0.004 to about 0.006, or from about 0.0002 to about 0.004% (w/w). In some further embodiments, the EP2 receptor agonist is present at about 0.0002, 0.0003, 0.0004, 0.0005, 0.0006, 0.0007, 0.0008, 0.0009, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, or 0.5% (w/w). In some further embodiments, the EP2 receptor agonist is present in an amount of about 0.0002% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the EP2 receptor agonist is a compound of Formula




embedded image


In other embodiments, the EP2 receptors agonist is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of Formula (IIIa). In some further embodiments, the EP2 receptor agonist is present in an amount approximately equal to or less than about 0.1% w/w. In some further embodiments, the EP2 receptor agonist is present from about 0.001 to about 0.1, from about 0.002 to about 0.1, from about 0.003 to about 0.1, from about 0.004 to about 0.1, from about 0.005 to about 0.1, from about 0.006 to about 0.1, from about 0.007 to about 0.1, from about 0.008 to about 0.1, from about 0.009 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.001 to about 0.08, from about 0.002 to about 0.08, from about 0.003 to about 0.08, from about 0.004 to about 0.08, from about 0.005 to about 0.08, from about 0.006 to about 0.08, from about 0.007 to about 0.08, from about 0.008 to about 0.08, from about 0.009 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, from about 0.07 to about 0.08, from about 0.001 to about 0.06, from about 0.002 to about 0.06, from about 0.003 to about 0.06, from about 0.004 to about 0.06, from about 0.005 to about 0.06, from about 0.006 to about 0.06, from about 0.007 to about 0.06, from about 0.008 to about 0.06, from about 0.009 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.003 to about 0.04, from about 0.004 to about 0.04, from about 0.005 to about 0.04, from about 0.006 to about 0.04, from about 0.007 to about 0.04, from about 0.008 to about 0.04, from about 0.009 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.003 to about 0.02, from about 0.004 to about 0.02, from about 0.005 to about 0.02, from about 0.006 to about 0.02, from about 0.007 to about 0.02, from about 0.008 to about 0.02, from about 0.009 to about 0.02, from about 0.01 to about 0.02, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.003 to about 0.01, from about 0.004 to about 0.01, from about 0.005 to about 0.01, from about 0.006 to about 0.01, from about 0.007 to about 0.01, from about 0.008 to about 0.01, or from about 0.009 to about 0.01% (w/w). In some further embodiments, the EP2 receptor agonist is present at about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% (w/w). In some further embodiments, the EP2 receptor agonist is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the active pharmaceutical ingredient is a muscarinic receptor agonist. A muscarinic receptor agonist is an agent that enhances or increases the activity of the muscarinic acetylcholine receptor. Muscarinic receptor agonists may bind directly to the muscarinic acetylcholine receptor. Examples of a muscarinic receptor agonist include without limitation, aceclidine, arecoline, cevimeline and pilocarpine. In some embodiments, the muscarinic receptor agonist is pilocarpine. In other embodiments, the muscarinic receptor agonist is any appropriate pharmaceutical salt, prodrug and/or analog of pilocarpine. In some further embodiments, the pilocarpine is present in an amount approximately equal to or less than about 8% w/w. In some embodiments, the pilocarpine is present from about 0.01 to about 8, from about 0.05 to about 8, from about 0.1 to about 8, from about 0.5 to about 8, from about 1 to about 8, from about 1.5 to about 8, from about 2 to about 8, from about 2.5 to about 8, from about 3 to about 8, from about 3.5 to about 8, from about 4 to about 8, from about 4.5 to about 8, from about 5 to about 8, from about 5.5 to about 8, from about 6 to about 8, from about 6.5 to about 8, from about 7 to about 8, from about 7.5 to about 8, from about 0.01 to about 7.5, from about 0.05 to about 7.5, from about 0.1 to about 7.5, from about 0.5 to about 7.5, from about 1 to about 7.5, from about 1.5 to about 7.5, from about 2 to about 7.5, from about 2.5 to about 7.5, from about 3 to about 7.5, from about 3.5 to about 7.5, from about 4 to about 7.5, from about 4.5 to about 7.5, from about 5 to about 7.5, from about 5.5 to about 7.5, from about 6 to about 7.5, from about 6.5 to about 7.5, from about 7 to about 7.5, from about 0.01 to about 7, from about 0.05 to about 7, from about 0.1 to about 7, from about 0.5 to about 7, from about 1 to about 7, from about 1.5 to about 7, from about 2 to about 7, from about 2.5 to about 7, from about 3 to about 7, from about 3.5 to about 7, from about 4 to about 7, from about 4.5 to about 7, from about 5 to about 7, from about 5.5 to about 7, from about 6 to about 7, from about 6.5 to about 7, from about 0.01 to about 6.5, from about 0.05 to about 6.5, from about 0.1 to about 6.5, from about 0.5 to about 6.5, from about 1 to about 6.5, from about 1.5 to about 6.5, from about 2 to about 6.5, from about 2.5 to about 6.5, from about 3 to about 6.5, from about 3.5 to about 6.5, from about 4 to about 6.5, from about 4.5 to about 6.5, from about 5 to about 6.5, from about 5.5 to about 6.5, or from about 6 to about 6.5% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the pilocarpine is present from about 0.01 to about 6, from about 0.05 to about 6, from about 0.1 to about 6, from about 0.5 to about 6, from about 1 to about 6, from about 1.5 to about 6, from about 2 to about 6, from about 2.5 to about 6, from about 3 to about 6, from about 3.5 to about 6, from about 4 to about 6, from about 4.5 to about 6, from about 5 to about 6, from about 5.5 to about 6, from about 0.01 to about 5.5, from about 0.05 to about 5.5, from about 0.1 to about 5.5, from about 0.5 to about 5.5, from about 1 to about 5.5, from about 1.5 to about 5.5, from about 2 to about 5.5, from about 2.5 to about 5.5, from about 3 to about 5.5, from about 3.5 to about 5.5, from about 4 to about 5.5, from about 4.5 to about 5.5, from about 5 to about 5.5, from about 0.01 to about 5, from about 0.05 to about 5, from about 0.1 to about 5, from about 0.5 to about 5, from about 1 to about 5, from about 1.5 to about 5, from about 2 to about 5, from about 2.5 to about 5, from about 3 to about 5, from about 3.5 to about 5, or from about 4 to about 5% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the pilocarpine is present from about 4.5 to about 5, from about 0.01 to about 4.5, from about 0.05 to about 4.5, from about 0.1 to about 4.5, from about 0.5 to about 4.5, from about 1 to about 4.5, from about 1.5 to about 4.5, from about 2 to about 4.5, from about 2.5 to about 4.5, from about 3 to about 4.5, from about 3.5 to about 4.5, from about 4 to about 4.5, from about 0.01 to about 4, from about 0.05 to about 4, from about 0.1 to about 4, from about 0.5 to about 4, from about 1 to about 4, from about 1.5 to about 4, from about 2 to about 4, from about 2.5 to about 4, from about 3 to about 4, from about 3.5 to about 4, from about 0.01 to about 3.5, from about 0.05 to about 3.5, from about 0.1 to about 3.5, from about 0.5 to about 3.5, from about 1 to about 3.5, from about 1.5 to about 3.5, from about 2 to about 3.5, from about 2.5 to about 3.5, from about 3 to about 3.5, from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.01 to about 0.1, from about 0.05 to about 0.1, or from about 0.01 to about 0.05% w/w. In some embodiments, the pilocarpine is present at about 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, or 8% (w/w). In some embodiments, the pilocarpine is present in an amount of about 0.01% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the active pharmaceutical ingredient is a prostaglandin analog. A prostaglandin analog is a compound, agent or molecule capable of binding a prostaglandin receptor. The structure of a prostaglandin analog may be similar to a natural prostaglandin. Examples of prostaglandin analogs include without limitation, bimatoprost, latanoprost, and travoprost. Additional examples include any pharmaceutical salts, any prodrugs and/or any functional analogs of bimatoprost, travoprost and latanoprost. In some embodiments, the prostaglandin analog is bimatoprost. Bimatoprost refers, in the customary sense, to CAS Registry No. 155206-00-1. In other embodiments, the prostaglandin analog is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of bimatoprost. In some embodiments, bimatoprost is present in an amount approximately equal to or less than about 0.1% w/w. In some embodiments, bimatoprost is present from about 0.001 to about 0.1, from about 0.002 to about 0.1, from about 0.003 to about 0.1, from about 0.004 to about 0.1, from about 0.005 to about 0.1, from about 0.006 to about 0.1, from about 0.007 to about 0.1, from about 0.008 to about 0.1, from about 0.009 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.001 to about 0.08, from about 0.002 to about 0.08, from about 0.003 to about 0.08, from about 0.004 to about 0.08, from about 0.005 to about 0.08, from about 0.006 to about 0.08, from about 0.007 to about 0.08, from about 0.008 to about 0.08, from about 0.009 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, or from about 0.07 to about 0.08% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, bimatoprost is present from about 0.001 to about 0.06, from about 0.002 to about 0.06, from about 0.003 to about 0.06, from about 0.004 to about 0.06, from about 0.005 to about 0.06, from about 0.006 to about 0.06, from about 0.007 to about 0.06, from about 0.008 to about 0.06, from about 0.009 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.003 to about 0.04, from about 0.004 to about 0.04, from about 0.005 to about 0.04, from about 0.006 to about 0.04, from about 0.007 to about 0.04, from about 0.008 to about 0.04, from about 0.009 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.003 to about 0.02, from about 0.004 to about 0.02, from about 0.005 to about 0.02, from about 0.006 to about 0.02, from about 0.007 to about 0.02, from about 0.008 to about 0.02, from about 0.009 to about 0.02, from about 0.01 to about 0.02, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.003 to about 0.01, from about 0.004 to about 0.01, from about 0.005 to about 0.01, from about 0.006 to about 0.01, from about 0.007 to about 0.01, from about 0.008 to about 0.01, or from about 0.009 to about 0.01% (w/w). In some embodiments, bimatoprost is present at about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% (w/w). In some embodiments, bimatoprost is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In other embodiments, the prostaglandin analog is latanoprost. Latanoprost refers, in the customary sense, to CAS Registry No. 130209-82-4. In other embodiments, the prostaglandin analog is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of latanoprost. In some embodiments, the latanoprost is present in an amount approximately equal to or less than about 0.1% w/w. In some embodiments, latanoprost is present from about 0.0003 to about 0.1, from about 0.0005 to about 0.1, from about 0.0007 to about 0.1, from about 0.0009 to about 0.1, from about 0.001 to about 0.1, from about 0.003 to about 0.1, from about 0.005 to about 0.1, from about 0.007 to about 0.1, from about 0.009 to about 0.1, from about 0.01 to about 0.1, from about 0.03 to about 0.1, from about 0.05 to about 0.1, from about 0.07 to about 0.1, from about 0.09 to about 0.1, from about 0.0003 to about 0.09, from about 0.0005 to about 0.09, from about 0.0007 to about 0.09, from about 0.0009 to about 0.09, from about 0.001 to about 0.09, from about 0.003 to about 0.09, from about 0.005 to about 0.09, from about 0.007 to about 0.09, from about 0.009 to about 0.09, from about 0.01 to about 0.09, from about 0.03 to about 0.09, from about 0.05 to about 0.09, from about 0.07 to about 0.09, from about 0.0003 to about 0.07, from about 0.0005 to about 0.07, from about 0.0007 to about 0.07, from about 0.0009 to about 0.07, from about 0.001 to about 0.07, from about 0.003 to about 0.07, from about 0.005 to about 0.07, from about 0.007 to about 0.07, from about 0.009 to about 0.07, from about 0.01 to about 0.07, from about 0.03 to about 0.07, from about 0.05 to about 0.07, from about 0.0003 to about 0.05, from about 0.0005 to about 0.05, from about 0.0007 to about 0.05, from about 0.0009 to about 0.05, from about 0.001 to about 0.05, from about 0.003 to about 0.05, from about 0.005 to about 0.05, from about 0.007 to about 0.05, from about 0.009 to about 0.05, from about 0.01 to about 0.05, or from about 0.03 to about 0.05% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, latanoprost is present from about 0.0003 to about 0.03, from about 0.0005 to about 0.03, from about 0.0007 to about 0.03, from about 0.0009 to about 0.03, from about 0.001 to about 0.03, from about 0.003 to about 0.03, from about 0.005 to about 0.03, from about 0.007 to about 0.03, from about 0.009 to about 0.03, from about 0.01 to about 0.03, from about 0.0003 to about 0.01, from about 0.0005 to about 0.01, from about 0.0007 to about 0.01, from about 0.0009 to about 0.01, from about 0.001 to about 0.01, from about 0.003 to about 0.01, from about 0.005 to about 0.01, from about 0.007 to about 0.01, from about 0.009 to about 0.01, from about 0.0003 to about 0.009, from about 0.0005 to about 0.009, from about 0.0007 to about 0.009, from about 0.0009 to about 0.009, from about 0.001 to about 0.009, from about 0.003 to about 0.009, from about 0.005 to about 0.009, from about 0.007 to about 0.009, from about 0.0003 to about 0.007, from about 0.0005 to about 0.007, from about 0.0007 to about 0.007, from about 0.0009 to about 0.007, from about 0.001 to about 0.007, from about 0.003 to about 0.007, from about 0.005 to about 0.007, from about 0.0003 to about 0.005, from about 0.0005 to about 0.005, from about 0.0007 to about 0.005, from about 0.0009 to about 0.005, from about 0.001 to about 0.005, from about 0.003 to about 0.005, from about 0.0003 to about 0.003, from about 0.0005 to about 0.003, from about 0.0007 to about 0.003, from about 0.0009 to about 0.003, from about 0.001 to about 0.003, from about 0.0003 to about 0.001, from about 0.0005 to about 0.001, from about 0.0007 to about 0.001, from about 0.0009 to about 0.001, from about 0.0003 to about 0.0009, from about 0.0005 to about 0.0009, from about 0.0007 to about 0.0009, from about 0.0003 to about 0.0007, from about 0.0005 to about 0.0007, or from about 0.0003 to about 0.0005% (w/w). In some embodiments, the latanoprost is present at about 0.1, 0.09, 0.07, 0.05, 0.03, 0.01, 0.009, 0.007, 0.005, 0.003, 0.001, 0.0009, 0.0007, 0.0005, or 0.0003% (w/w). In some embodiments, the latanoprost is present in an amount of about 0.0003% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the prostaglandin analog is travoprost. Travoprost refers, in the customary sense, to CAS Registry No. 157283-68-6. In other embodiments, the prostaglandin analog is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of travoprost. In some embodiments, the travoprost is present in an amount approximately equal to or less than about 0.1% w/w. In some embodiments, the travoprost is present in an amount from about 0.0002 to about 0.1, from about 0.0004 to about 0.1, from about 0.0006 to about 0.1, from about 0.0008 to about 0.1, from about 0.001 to about 0.1, from about 0.002 to about 0.1, from about 0.004 to about 0.1, from about 0.006 to about 0.1, from about 0.008 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.04 to about 0.1, from about 0.06 to about 0.1, from about 0.08 to about 0.1, from about 0.0002 to about 0.08, from about 0.0004 to about 0.08, from about 0.0006 to about 0.08, from about 0.0008 to about 0.08, from about 0.001 to about 0.08, from about 0.002 to about 0.08, from about 0.004 to about 0.08, from about 0.006 to about 0.08, from about 0.008 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.04 to about 0.08, from about 0.06 to about 0.08, from about 0.0002 to about 0.06, from about 0.0004 to about 0.06, from about 0.0006 to about 0.06, from about 0.0008 to about 0.06, from about 0.001 to about 0.06, from about 0.002 to about 0.06, from about 0.004 to about 0.06, from about 0.006 to about 0.06, from about 0.008 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, or from about 0.04 to about 0.06% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the travoprost is present in an amount from about 0.0002 to about 0.04, from about 0.0004 to about 0.04, from about 0.0006 to about 0.04, from about 0.0008 to about 0.04, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.004 to about 0.04, from about 0.006 to about 0.04, from about 0.008 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.0002 to about 0.02, from about 0.0004 to about 0.02, from about 0.0006 to about 0.02, from about 0.0008 to about 0.02, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.004 to about 0.02, from about 0.006 to about 0.02, from about 0.008 to about 0.02, from about 0.01 to about 0.02, from about 0.0002 to about 0.01, from about 0.0004 to about 0.01, from about 0.0006 to about 0.01, from about 0.0008 to about 0.01, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.004 to about 0.01, from about 0.006 to about 0.01, from about 0.008 to about 0.01, from about 0.0002 to about 0.008, from about 0.0004 to about 0.008, from about 0.0006 to about 0.008, from about 0.0008 to about 0.008, from about 0.001 to about 0.008, from about 0.002 to about 0.008, from about 0.004 to about 0.008, from about 0.006 to about 0.008, from about 0.0002 to about 0.006, from about 0.0004 to about 0.006, from about 0.0006 to about 0.006, from about 0.0008 to about 0.006, from about 0.001 to about 0.006, from about 0.002 to about 0.006, from about 0.004 to about 0.006, from about 0.0002 to about 0.004, from about 0.0004 to about 0.004, from about 0.0006 to about 0.004, from about 0.0008 to about 0.004, from about 0.001 to about 0.004, from about 0.002 to about 0.004, from about 0.0002 to about 0.002, from about 0.0004 to about 0.002, from about 0.0006 to about 0.002, from about 0.0008 to about 0.002, from about 0.001 to about 0.002, from about 0.0002 to about 0.001, from about 0.0004 to about 0.001, from about 0.0006 to about 0.001, from about 0.0008 to about 0.001, from about 0.0002 to about 0.0008, from about 0.0004 to about 0.0008, from about 0.0006 to about 0.0008, from about 0.0002 to about 0.0006, from about 0.0004 to about 0.0006, or from about 0.0002 to about 0.0004% (w/w). In some embodiments, the travoprost is present at about 0.1, 0.08, 0.06, 0.04, 0.02, 0.01, 0.008, 0.006, 0.004, 0.002, 0.001, 0.0008, 0.0006, 0.0004, or 0.0002% (w/w). In some embodiments, travoprost is present in an amount of about 0.0002% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


As mentioned above the composition provided herein may include a vasoconstrictor agent. A vasoconstrictor agent is an agent having a vasoconstriction effect on blood vessel within an organism (e.g. a mammal such as a human). Vasoconstriction typically results from the narrowing of blood vessels resulting from contraction of the muscular wall of the vessels. Vasoconstriction may be a mechanism by which the body regulates and maintains mean arterial pressure. Therefore, vasoconstrictors or vasoconstrictor agents are often agents causing a general increase in systemic blood pressure, but at the same time may cause a localized reduction in blood flow. In some embodiments, the vasoconstrictor agent is an alpha adrenergic agonist. An alpha adrenergic agonist is an agent (e.g., drug, compound), which stimulates (e.g. selectively stimulates) alpha adrenergic receptors. Alpha adrenergic receptors are G protein-coupled receptors that may be bound by noradrenalin and adrenaline. In some embodiments, binding of an agonist to an alpha adrenergic receptor leads to vasoconstriction, which causes a sympathetic response, where the heart rate increases, the pupils dilate and blood flow is being diverted from non-essential organs to the skeletal muscle. A non-limiting example of an alpha adrenergic agonist is brimonidine. In some embodiments, the alpha adrenergic agonist is brimonidine. Brimonidine refers, in the customary sense, to CAS Registry No. 59803-98-4. In other embodiments, the alpha adrenergic agonist is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of brimonidine. In some embodiments, the brimonidine is present in an amount approximately equal to or less than 1% w/w. In some embodiments, the brimonidine is present from about 0.001 to about 0.1, from about 0.002 to about 0.1, from about 0.003 to about 0.1, from about 0.004 to about 0.1, from about 0.005 to about 0.1, from about 0.006 to about 0.1, from about 0.007 to about 0.1, from about 0.008 to about 0.1, from about 0.009 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.001 to about 0.08, from about 0.002 to about 0.08, from about 0.003 to about 0.08, from about 0.004 to about 0.08, from about 0.005 to about 0.08, from about 0.006 to about 0.08, from about 0.007 to about 0.08, from about 0.008 to about 0.08, from about 0.009 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, or from about 0.07 to about 0.08% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the brimonidine is present from about 0.001 to about 0.06, from about 0.002 to about 0.06, from about 0.003 to about 0.06, from about 0.004 to about 0.06, from about 0.005 to about 0.06, from about 0.006 to about 0.06, from about 0.007 to about 0.06, from about 0.008 to about 0.06, from about 0.009 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.003 to about 0.04, from about 0.004 to about 0.04, from about 0.005 to about 0.04, from about 0.006 to about 0.04, from about 0.007 to about 0.04, from about 0.008 to about 0.04, from about 0.009 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.003 to about 0.02, from about 0.004 to about 0.02, from about 0.005 to about 0.02, from about 0.006 to about 0.02, from about 0.007 to about 0.02, from about 0.008 to about 0.02, from about 0.009 to about 0.02, from about 0.01 to about 0.02, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.003 to about 0.01, from about 0.004 to about 0.01, from about 0.005 to about 0.01, from about 0.006 to about 0.01, from about 0.007 to about 0.01, from about 0.008 to about 0.01, or from about 0.009 to about 0.01% (w/w). In some embodiments, the brimonidine is present at about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% (w/w). In some embodiments, the brimonidine is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the alpha adrenergic agonist is an alpha adrenergic agonist compound. In some embodiments, the alpha adrenergic agonist compound has the Formula




embedded image


In some embodiments, the alpha adrenergic agonist compound has the Formula




embedded image


In some embodiments, the alpha adrenergic agonist compound has the Formula




embedded image


In some embodiments, the alpha adrenergic agonist compound has the Formula




embedded image


In some embodiments, the alpha adrenergic agonist compound has the Formula




embedded image


In some embodiments, the alpha adrenergic agonist compound has the Formula




embedded image


In other embodiments, the alpha adrenergic agonist is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of Formula (IVa), (Va), (VI), (VIIa), (VIIb), (VIIIa), or (VIIIb). In other embodiments, the alpha adrenergic agonist is any appropriate pharmaceutical salt, prodrug and/or analog of the compound of Formula (IVa), (Va), (VI), (VIIa), or (VIIIa).


In some embodiments, the alpha adrenergic agonist compound is present in an amount approximately equal to or less than 1% w/w. In some embodiments, the alpha adrenergic agonist compound is present from about 0.001 to about 0.1, from about 0.002 to about 0.1, from about 0.003 to about 0.1, from about 0.004 to about 0.1, from about 0.005 to about 0.1, from about 0.006 to about 0.1, from about 0.007 to about 0.1, from about 0.008 to about 0.1, from about 0.009 to about 0.1, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.001 to about 0.08, from about 0.002 to about 0.08, from about 0.003 to about 0.08, from about 0.004 to about 0.08, from about 0.005 to about 0.08, from about 0.006 to about 0.08, from about 0.007 to about 0.08, from about 0.008 to about 0.08, from about 0.009 to about 0.08, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, or from about 0.07 to about 0.08% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the alpha adrenergic agonist compound is present from about 0.001 to about 0.06, from about 0.002 to about 0.06, from about 0.003 to about 0.06, from about 0.004 to about 0.06, from about 0.005 to about 0.06, from about 0.006 to about 0.06, from about 0.007 to about 0.06, from about 0.008 to about 0.06, from about 0.009 to about 0.06, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.001 to about 0.04, from about 0.002 to about 0.04, from about 0.003 to about 0.04, from about 0.004 to about 0.04, from about 0.005 to about 0.04, from about 0.006 to about 0.04, from about 0.007 to about 0.04, from about 0.008 to about 0.04, from about 0.009 to about 0.04, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.001 to about 0.02, from about 0.002 to about 0.02, from about 0.003 to about 0.02, from about 0.004 to about 0.02, from about 0.005 to about 0.02, from about 0.006 to about 0.02, from about 0.007 to about 0.02, from about 0.008 to about 0.02, from about 0.009 to about 0.02, from about 0.01 to about 0.02, from about 0.001 to about 0.01, from about 0.002 to about 0.01, from about 0.003 to about 0.01, from about 0.004 to about 0.01, from about 0.005 to about 0.01, from about 0.006 to about 0.01, from about 0.007 to about 0.01, from about 0.008 to about 0.01, or from about 0.009 to about 0.01% (w/w). In some embodiments, the alpha adrenergic agonist compound is present at about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% (w/w). In some embodiments, the alpha adrenergic agonist compound is present in an amount of about 0.001% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In other embodiments, the vasoconstrictor agent is a beta adrenergic antagonist. A beta adrenergic antagonist is an agent (e.g., drug, compound), which inhibits (e.g. decreases) the stimulation of beta adrenergic receptors. Stimulation of beta adrenergic receptors induces smooth muscle relaxation, whereas blocking beta adrenergic receptors typically causes contraction of smooth muscles. Therefore, beta adrenergic antagonists may cause vasoconstriction. Examples of beta adrenergic antagonists include without limitation befunolol, betaxolol, carteolol, levobunolol, metipranolol, timolol, and mepindolol.


In some embodiments, the beta adrenergic antagonist is timolol. In some embodiments, the timolol is timolol maleate. Timolol maleate refers, in the customary sense, to CAS Registry No. 26839-75-8. The chemical name of timolol maleate is (−)-1-tert-butylamino-3-[(4-morpholino-1,2,5-thiodiazol-3yl)oxy]-2-propanol maleate. Timolol maleate has a molecular weight of 432.50 g/mol and is commercially available from Merck as TIMOPTIC®. In other embodiments, the timolol is timolol hemihydrate. In other embodiments, the beta adrenergic antagonist is any appropriate pharmaceutical salt, prodrug and/or analog of timolol. In some embodiments, the timolol is present in an amount approximately equal to or less than about 0.5% w/w. In some embodiments, the timolol is present from about 0.01 to about 1, from about 0.02 to about 1, from about 0.03 to about 1, from about 0.04 to about 1, from about 0.05 to about 1, from about 0.06 to about 1, from about 0.07 to about 1, from about 0.08 to about 1, from about 0.09 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0.6 to about 1, from about 0.7 to about 1, from about 0.8 to about 1, from about 0.9 to about 1, from about 0.01 to about 0.9, from about 0.02 to about 0.9, from about 0.03 to about 0.9, from about 0.04 to about 0.9, from about 0.05 to about 0.9, from about 0.06 to about 0.9, from about 0.07 to about 0.9, from about 0.08 to about 0.9, from about 0.09 to about 0.9, from about 0.1 to about 0.9, from about 0.2 to about 0.9, from about 0.3 to about 0.9, from about 0.4 to about 0.9, from about 0.5 to about 0.9, from about 0.6 to about 0.9, from about 0.7 to about 0.9, from about 0.8 to about 0.9, from about 0.01 to about 0.8, from about 0.02 to about 0.8, from about 0.03 to about 0.8, from about 0.04 to about 0.8, from about 0.05 to about 0.8, from about 0.06 to about 0.8, from about 0.07 to about 0.8, from about 0.08 to about 0.8, from about 0.09 to about 0.8, from about 0.1 to about 0.8, from about 0.2 to about 0.8, from about 0.3 to about 0.8, from about 0.4 to about 0.8, from about 0.5 to about 0.8, from about 0.6 to about 0.8, or from about 0.7 to about 0.8% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the timolol is present from about 0.01 to about 0.7, from about 0.02 to about 0.7, from about 0.03 to about 0.7, from about 0.04 to about 0.7, from about 0.05 to about 0.7, from about 0.06 to about 0.7, from about 0.07 to about 0.7, from about 0.08 to about 0.7, from about 0.09 to about 0.7, from about 0.1 to about 0.7, from about 0.2 to about 0.7, from about 0.3 to about 0.7, from about 0.4 to about 0.7, from about 0.5 to about 0.7, from about 0.6 to about 0.7, from about 0.01 to about 0.6, from about 0.02 to about 0.6, from about 0.03 to about 0.6, from about 0.04 to about 0.6, from about 0.05 to about 0.6, from about 0.06 to about 0.6, from about 0.07 to about 0.6, from about 0.08 to about 0.6, from about 0.09 to about 0.6, from about 0.1 to about 0.6, from about 0.2 to about 0.6, from about 0.3 to about 0.6, from about 0.4 to about 0.6, from about 0.5 to about 0.6, from about 0.01 to about 0.5, from about 0.02 to about 0.5, from about 0.03 to about 0.5, from about 0.04 to about 0.5, from about 0.05 to about 0.5, from about 0.06 to about 0.5, from about 0.07 to about 0.5, from about 0.08 to about 0.5, from about 0.09 to about 0.5, from about 0.1 to about 0.5, from about 0.2 to about 0.5, from about 0.3 to about 0.5, from about 0.4 to about 0.5, from about 0.01 to about 0.4, from about 0.02 to about 0.4, from about 0.03 to about 0.4, from about 0.04 to about 0.4, from about 0.05 to about 0.4, from about 0.06 to about 0.4, from about 0.07 to about 0.4, from about 0.08 to about 0.4, from about 0.09 to about 0.4, from about 0.1 to about 0.4, from about 0.2 to about 0.4, from about 0.3 to about 0.4, from about 0.01 to about 0.3, from about 0.02 to about 0.3, from about 0.03 to about 0.3, from about 0.04 to about 0.3, from about 0.05 to about 0.3, from about 0.06 to about 0.3, from about 0.07 to about 0.3, from about 0.08 to about 0.3, from about 0.09 to about 0.3, from about 0.1 to about 0.3, or from about 0.2 to about 0.3% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


In some embodiments, the timolol is present from about 0.01 to about 0.2, from about 0.02 to about 0.2, from about 0.03 to about 0.2, from about 0.04 to about 0.2, from about 0.05 to about 0.2, from about 0.06 to about 0.2, from about 0.07 to about 0.2, from about 0.08 to about 0.2, from about 0.09 to about 0.2, from about 0.1 to about 0.2, from about 0.01 to about 0.1, from about 0.02 to about 0.1, from about 0.03 to about 0.1, from about 0.04 to about 0.1, from about 0.05 to about 0.1, from about 0.06 to about 0.1, from about 0.07 to about 0.1, from about 0.08 to about 0.1, from about 0.09 to about 0.1, from about 0.01 to about 0.09, from about 0.02 to about 0.09, from about 0.03 to about 0.09, from about 0.04 to about 0.09, from about 0.05 to about 0.09, from about 0.06 to about 0.09, from about 0.07 to about 0.09, from about 0.08 to about 0.09, from about 0.01 to about 0.08, from about 0.02 to about 0.08, from about 0.03 to about 0.08, from about 0.04 to about 0.08, from about 0.05 to about 0.08, from about 0.06 to about 0.08, from about 0.07 to about 0.08, from about 0.01 to about 0.07, from about 0.02 to about 0.07, from about 0.03 to about 0.07, from about 0.04 to about 0.07, from about 0.05 to about 0.07, from about 0.06 to about 0.07, from about 0.01 to about 0.06, from about 0.02 to about 0.06, from about 0.03 to about 0.06, from about 0.04 to about 0.06, from about 0.05 to about 0.06, from about 0.01 to about 0.05, from about 0.02 to about 0.05, from about 0.03 to about 0.05, from about 0.04 to about 0.05, from about 0.01 to about 0.04, from about 0.02 to about 0.04, from about 0.03 to about 0.04, from about 0.01 to about 0.03, from about 0.02 to about 0.03, or from about 0.01 to about 0.02% w/w. In some embodiments, the timolol is present at about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1% w/w. In some embodiments, the timolol is present in amount of about 0.05% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


The active pharmaceutical ingredient provided herein may be an anti-infective agent. An anti-infective agent is an agent capable of inhibiting (e.g. reducing) growth, spreading of or killing of bacterial, fungal or viral organisms. Examples of anti-infective agents include antibacterial, antibiotic, antifungal, antiprotozoan, and antiviral agents. Thus, in some embodiments, the active pharmaceutical ingredient is an anti-infective agent. In some embodiments, the anti-infective agent is gatifloxacin. Gatifloxacin refers, in the customary sense, to CAS Registry No. 112811-59-3. The chemical name of gatifloxacin is 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid. In other embodiments, the anti-infective agent is any appropriate pharmaceutical salt, prodrug and/or analog of gatifloxacin. In some embodiments, gatifloxacin is present in an amount approximately equal to or less than about 1% w/w. In some embodiments, the gatifloxacin is present from about 0.01 to about 3, from about 0.05 to about 3, from about 0.1 to about 3, from about 0.5 to about 3, from about 1 to about 3, from about 1.5 to about 3, from about 2 to about 3, from about 2.5 to about 3, from about 0.01 to about 2.5, from about 0.05 to about 2.5, from about 0.1 to about 2.5, from about 0.5 to about 2.5, from about 1 to about 2.5, from about 1.5 to about 2.5, from about 2 to about 2.5, from about 0.01 to about 2, from about 0.05 to about 2, from about 0.1 to about 2, from about 0.5 to about 2, from about 1 to about 2, from about 1.5 to about 2, from about 0.01 to about 1.5, from about 0.05 to about 1.5, from about 0.1 to about 1.5, from about 0.5 to about 1.5, from about 1 to about 1.5, from about 0.01 to about 1, from about 0.05 to about 1, from about 0.1 to about 1, from about 0.5 to about 1, from about 0.01 to about 0.5, from about 0.05 to about 0.5, from about 0.1 to about 0.5, from about 0.01 to about 0.1, from about 0.05 to about 0.1, or from about 0.01 to about 0.0.5% w/w. In some embodiments, the gatifloxacin is present at about 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, or 3% w/w. In some embodiments, the gatifloxacin is present in an amount of about 0.1% w/w. The numerical values above represent amounts of the active ingredient in % (w/w).


Compositions and products according to the embodiments of the present invention comprise a silicone excipient. A silicone excipient as defined herein is a pharmaceutically acceptable silicone-based agent with which the active pharmaceutical ingredient is combined to facilitate the application. As provided herein a silicone excipient may include one or more silicone excipient blends. A silicone excipient blend may include two or more silicone compounds, where the constituent silicone compounds form a uniform mixture of a particular character, quality, or consistency. For example, a first silicone compound and a second silicone compound forming a blend may have different viscosities. The first silicone compound may have a low viscosity and therefore be a in a fluid state, whereas the second silicone compound may have a high viscosity and therefore be in a solid (gum) state. By combining a specific amount of the first silicone compound with a specific amount of the second silicone compound a blend with a specific viscosity is generated. For example, the viscosity of a blend including an amount of a low viscosity silicone compound and an amount of a high viscosity silicone compound may have a viscosity which is higher than the viscosity of the low viscosity silicone compound and lower than the viscosity of the high viscosity silicone compound. Non-limiting examples of silicone compounds useful for the silicone excipient blends provided herein are dimethiconol, dimethicone, cyclopentasiloxane, decamethylcyclopentasiloxane, alkylmethyl siloxane copolyol, and stearyltrimethylsilane.


In some embodiments, the silicone excipient forms part of a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, a fourth silicone excipient blend or a fifth silicone excipient blend. In other embodiments, the silicone excipient forms part of a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, and a fourth silicone excipient blend. In other embodiments, the silicone excipient forms part of a first silicone excipient blend.


In some embodiments, the silicone excipient is a silicone excipient blend. In some embodiments, a non-aqueous composition may include a plurality of excipient blends. For example, the non-aqueous composition may include a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, a fourth silicone excipient blend, a fifth silicone excipient blend, a sixth silicone excipient blend and/or a seventh silicone excipient blend. In other embodiments, the non-aqueous composition includes a first silicone excipient blend and a second silicone excipient blend. In other embodiments, the non-aqueous composition includes a first silicone excipient blend, a second silicone excipient blend and a third silicone excipient blend. In other embodiments, the non-aqueous composition includes a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, and a fourth silicone excipient blend. Where, the non-aqueous composition includes a plurality of excipient blends (e.g. a “first, second, third, fourth, fifth, sixth and/or seventh” silicone excipient blend), each excipient blend may be different. For example, each of the first, second, third, fourth, fifth, sixth and/or seventh silicone excipient blends, in some embodiments, may be different (i.e. chemically different or having at least one different chemical component such as a silicone based chemical component). In some embodiments, the second silicone excipient blend as used herein is chemically different from the other silicone excipient blends present in the non-aqueous composition (e.g. first, third, fourth, fifth, sixth or seventh silicone excipient blend). In some embodiments, a “third” silicone excipient blend is different from the other, first, second, fourth, fifth, sixth, or seventh silicone excipient blend. A first, second, third, fourth, fifth, sixth or seventh silicone excipient blend can be any silicone excipient blend provided herein (e.g. dimethiconol, dimethicone, cyclopentasiloxane, decamethylcyclopentasiloxane, alkylmethyl siloxane copolyol, alkylmethyl siloxane and stearyltrimethylsilane) or any silicone excipient blend suitable for the non-aqueous compositions according to the embodiments provided herein.


In some embodiments, the first silicone excipient blend includes dimethicone and dimethiconol. Dimethicone, also known in the art as polydimethylsiloxane (PDMS) is a silicon compound having the chemical formula CH3[Si(CH3)2O]nSi(CH3)3, where n is the number of repeating monomer [SiO(CH3)2] units. Dimethicone refers, in the customary sense, to CAS Registry No. 70131-67-8. Dimethiconol is a hydroxyl-terminated polydimethylsiloxane and refers, in the customary sense, to CAS Registry No. 63148-62-9. Depending on the number of repeating methylsiloxane units, the silicone compounds dimethicone and dimethiconol may exhibit different viscosities. Where the number of methylsiloxane units in the silicone compound is high the viscosity is high and where the number of methylsiloxane units is low the viscosity is low. A non-limiting example of a silicone excipient blend including dimethicone and dimethiconol useful for the compositions provided herein is Dimethiconol Blend®20. Dimethiconol Blend®20 is a clear solution of approximately 6% of an ultra-high viscosity hydroxyl-terminated polydimethylsiloxane gum (dimethiconol) in a low viscosity (non-volatile) silicone fluid (dimethicone). In some embodiments, the first silicone excipient blend is present from about 1% w/w to about 10% w/w. In some embodiments, the first silicone excipient blend is present from about 2% w/w to about 10% w/w, from about 3% w/w to about 10% w/w, from about 4% w/w to about 10% w/w, from about 5% w/w to about 10% w/w, from about 6% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 2% w/w to about 9% w/w, from about 3% w/w to about 9% w/w, from about 4% w/w to about 9% w/w, from about 5% w/w to about 9% w/w, from about 6% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 2% w/w to about 8% w/w, from about 3% w/w to about 8% w/w, from about 4% w/w to about 8% w/w, from about 5% w/w to about 8% w/w, from about 6% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, from about 2% w/w to about 7% w/w, from about 3% w/w to about 7% w/w, from about 4% w/w to about 7% w/w, from about 5% w/w to about 7% w/w, from about 6% w/w to about 7% w/w, from about 2% w/w to about 6% w/w, from about 3% w/w to about 6% w/w, from about 4% w/w to about 6% w/w, from about 5% w/w to about 6% w/w, from about 2% w/w to about 5% w/w, from about 3% w/w to about 5% w/w, from about 4% w/w to about 5% w/w, from about 2% w/w to about 4% w/w, from about 3% w/w to about 4% w/w, or from about 2% w/w to about 3% w/w. In some embodiments, the first silicone excipient blend is present at about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w). The first silicone excipient (e.g. excipient blend) may be present in a quantity sufficient (q.s.) that the total of all components (i.e. active pharmaceutical ingredients, silicone excipient blends, and lipid excipients) present in a non-aqueous composition equals 100% w/w. For example where the total of active pharmaceutical ingredients, silicone excipient blends, and lipid excipients in a non-aqueous composition is 36.35%, the amount of the first silicone excipient is 63.65% w/w thereby resulting in a total of 100% w/w for all components present in the non-aqueous composition.


In some embodiments, the second silicone excipient blend includes cyclopentasiloxane and dimethicone cross polymer. Cyclopentasiloxane is a cyclic dimethicone including five monomer [SiO(CH3)2] units and is therefore also called decamethylcyclopentasiloxane. A dimethicone cross polymer is a high molecular weight silicone elastomer, where a methyl group in one or more of the monomer [SiO(CH3)2] units is replaced with an hydrocarbon side chain of variable length (e.g. C8H17). A non-limiting example of a silicone excipient blend including cyclopentasiloxane and dimethicone cross polymer that is useful for the compositions provided herein is Elastomer®10. Elastomer®10 is a mixture of 12% high molecular weight silicone elastomer (i.e. dimethicone cross polymer) in decamethylcyclopentasiloxane. In some embodiments, the second silicone excipient blend is present from about 5% w/w to about 10% w/w. In some embodiments, the second silicone excipient blend is present from about 5.5% w/w to about 10% w/w, from about 6% w/w to about 10% w/w, from about 6.5% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 7.5% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 8.5% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 9.5% w/w to about 10% w/w, from about 5% w/w to about 9.5% w/w, 5.5% w/w to about 9.5% w/w, from about 6% w/w to about 9.5% w/w, from about 6.5% w/w to about 9.5% w/w, from about 7% w/w to about 9.5% w/w, from about 7.5% w/w to about 9.5% w/w, from about 8% w/w to about 9.5% w/w, from about 8.5% w/w to about 9.5% w/w, from about 9% w/w to about 9.5% w/w, from about 5% w/w to about 9% w/w, 5.5% w/w to about 9% w/w, from about 6% w/w to about 9% w/w, from about 6.5% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 7.5% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 8.5% w/w to about 9% w/w, from about 5% w/w to about 8.5% w/w, 5.5% w/w to about 8.5% w/w, from about 6% w/w to about 8.5% w/w, from about 6.5% w/w to about 8.5% w/w, from about 7% w/w to about 8.5% w/w, from about 7.5% w/w to about 8.5% w/w, from about 8% w/w to about 8.5% w/w, from about 5% w/w to about 8% w/w, 5.5% w/w to about 8% w/w, from about 6% w/w to about 8% w/w, from about 6.5% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, from about 7.5% w/w to about 8% w/w, from about 5% w/w to about 7.5% w/w, 5.5% w/w to about 7.5% w/w, from about 6% w/w to about 7.5% w/w, from about 6.5% w/w to about 7.5% w/w, from about 7% w/w to about 7.5% w/w, from about 5% w/w to about 7% w/w, 5.5% w/w to about 7% w/w, from about 6% w/w to about 7% w/w, from about 6.5% w/w to about 7% w/w, from about 5% w/w to about 6.5% w/w, 5.5% w/w to about 6.5% w/w, or from about 6% w/w to about 6.5% w/w. In some embodiments, the second silicone excipient blend is present at about 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


In some further embodiments, the second silicone excipient blend includes cyclopentasiloxane and dimethicone cross polymer. Cyclopentasiloxane is a cyclic dimethicone including five monomer [SiO(CH3)2] units and is therefore also called decamethylcyclopentasiloxane. A dimethicone cross polymer is a high molecular weight silicone elastomer, where a methyl group in one or more of the monomer [SiO(CH3)2] units is replaced with an hydrocarbon side chain of variable length (e.g. C8H17). A non-limiting example of a silicone excipient blend including cyclopentasiloxane and dimethicone cross polymer that is useful for the compositions provided herein is Elastomer®10. Elastomer®10 is a mixture of 12% high molecular weight silicone elastomer (i.e. dimethicone cross polymer) in decamethylcyclopentasiloxane. In some embodiments, the second silicone excipient blend is present from about 5% w/w to about 20% w/w. In some embodiments, the second silicone excipient blend is present from about 6% w/w to about 20% w/w, from about 7% w/w to about 20% w/w, from about 8% w/w to about 20% w/w, from about 9% w/w to about 20% w/w, from about 10% w/w to about 20% w/w, from about 11% w/w to about 20% w/w, from about 12% w/w to about 20% w/w, from about 13% w/w to about 20% w/w, from about 14% w/w to about 20% w/w, from about 15% w/w to about 20% w/w, from about 16% w/w to about 20% w/w, from about 17% w/w to about 20% w/w, from about 18% w/w to about 20% w/w, from about 19% w/w to about 20% w/w, from about 6% w/w to about 19% w/w, from about 7% w/w to about 19% w/w, from about 8% w/w to about 19% w/w, from about 9% w/w to about 19% w/w, from about 10% w/w to about 19% w/w, from about 11% w/w to about 19% w/w, from about 12% w/w to about 19% w/w, from about 13% w/w to about 19% w/w, from about 14% w/w to about 19% w/w, from about 15% w/w to about 19% w/w, from about 16% w/w to about 19% w/w, from about 17% w/w to about 19% w/w, from about 18% w/w to about 19% w/w, from about 6% w/w to about 18% w/w, from about 7% w/w to about 18% w/w, from about 8% w/w to about 18% w/w, from about 9% w/w to about 18% w/w, from about 10% w/w to about 18% w/w, from about 11% w/w to about 18% w/w, from about 12% w/w to about 18% w/w, from about 13% w/w to about 18% w/w, from about 14% w/w to about 18% w/w, from about 15% w/w to about 18% w/w, from about 16% w/w to about 18% w/w, from about 17% w/w to about 18% w/w, from about 6% w/w to about 17% w/w, from about 7% w/w to about 17% w/w, from about 8% w/w to about 17% w/w, from about 9% w/w to about 17% w/w, from about 10% w/w to about 17% w/w, from about 11% w/w to about 17% w/w, from about 12% w/w to about 17% w/w, from about 13% w/w to about 17% w/w, from about 14% w/w to about 17% w/w, from about 15% w/w to about 17% w/w, from about 16% w/w to about 17% w/w, from about 6% w/w to about 16% w/w, from about 7% w/w to about 16% w/w, from about 8% w/w to about 16% w/w, from about 9% w/w to about 16% w/w, from about 10% w/w to about 16% w/w, from about 11% w/w to about 16% w/w, from about 12% w/w to about 16% w/w, from about 13% w/w to about 16% w/w, from about 14% w/w to about 16% w/w, from about 15% w/w to about 16% w/w, from about 6% w/w to about 15% w/w, from about 7% w/w to about 15% w/w, from about 8% w/w to about 15% w/w, from about 9% w/w to about 15% w/w, from about 10% w/w to about 15% w/w, from about 11% w/w to about 15% w/w, from about 12% w/w to about 15% w/w, from about 13% w/w to about 15% w/w, from about 14% w/w to about 15% w/w, from about 6% w/w to about 14% w/w, from about 7% w/w to about 14% w/w, from about 8% w/w to about 14% w/w, from about 9% w/w to about 14% w/w, from about 10% w/w to about 14% w/w, from about 11% w/w to about 14% w/w, from about 12% w/w to about 14% w/w, from about 13% w/w to about 14% w/w, from about 6% w/w to about 13% w/w, from about 7% w/w to about 13% w/w, from about 8% w/w to about 13% w/w, from about 9% w/w to about 13% w/w, from about 10% w/w to about 13% w/w, from about 11% w/w to about 13% w/w, from about 12% w/w to about 13% w/w, from about 6% w/w to about 12% w/w, from about 7% w/w to about 12% w/w, from about 8% w/w to about 12% w/w, from about 9% w/w to about 12% w/w, from about 10% w/w to about 12% w/w, from about 11% w/w to about 12% w/w, from about 6% w/w to about 11% w/w, from about 7% w/w to about 11% w/w, from about 8% w/w to about 11% w/w, from about 9% w/w to about 11% w/w, from about 10% w/w to about 11% w/w, from about 6% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 6% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 6% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, or from about 6% w/w to about 7% w/w. In some embodiments, the second silicone excipient blend is present at about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w). The second silicone excipient may be present in a quantity sufficient (q.s.) such that the total of all components (i.e. active pharmaceutical ingredients, silicone excipient blends, and lipid excipients) present in a non-aqueous composition equals 100% w/w. For example where the total of active pharmaceutical ingredients, silicone excipient blends, and lipid excipients in a non-aqueous composition is 36.35%, the amount of the second silicone excipient is 63.65% w/w thereby resulting in a total of 100% w/w for all components present in the non-aqueous composition.


In other embodiments, the third silicone excipient blend includes polydimethylcyclosiloxanes. Polydiemthylcyclosiloxanes are cyclic dimethicones including multiple monomer [SiO(CH3)2] units. A non-limiting example of a silicone excipient blend including polydimethylcyclosiloxanes is ST-Cyclomethicone®5-NF. ST-Cyclomethicone®5-NF is a clear, colorless, volatile polydimethylcyclosiloxane composed mainly of decamethylcyclopentasiloxane. In some embodiments, the third silicone excipient blend is present from about 5% w/w to about 10% w/w. In some embodiments, the third silicone excipient blend is present from about 5.5% w/w to about 10% w/w, from about 6% w/w to about 10% w/w, from about 6.5% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 7.5% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 8.5% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 9.5% w/w to about 10% w/w, from about 5% w/w to about 9.5% w/w, 5.5% w/w to about 9.5% w/w, from about 6% w/w to about 9.5% w/w, from about 6.5% w/w to about 9.5% w/w, from about 7% w/w to about 9.5% w/w, from about 7.5% w/w to about 9.5% w/w, from about 8% w/w to about 9.5% w/w, from about 8.5% w/w to about 9.5% w/w, from about 9% w/w to about 9.5% w/w, from about 5% w/w to about 9% w/w, 5.5% w/w to about 9% w/w, from about 6% w/w to about 9% w/w, from about 6.5% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 7.5% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 8.5% w/w to about 9% w/w, from about 5% w/w to about 8.5% w/w, 5.5% w/w to about 8.5% w/w, from about 6% w/w to about 8.5% w/w, from about 6.5% w/w to about 8.5% w/w, from about 7% w/w to about 8.5% w/w, from about 7.5% w/w to about 8.5% w/w, from about 8% w/w to about 8.5% w/w, from about 5% w/w to about 8% w/w, 5.5% w/w to about 8% w/w, from about 6% w/w to about 8% w/w, from about 6.5% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, from about 7.5% w/w to about 8% w/w, from about 5% w/w to about 7.5% w/w, 5.5% w/w to about 7.5% w/w, from about 6% w/w to about 7.5% w/w, from about 6.5% w/w to about 7.5% w/w, from about 7% w/w to about 7.5% w/w, from about 5% w/w to about 7% w/w, 5.5% w/w to about 7% w/w, from about 6% w/w to about 7% w/w, from about 6.5% w/w to about 7% w/w, from about 5% w/w to about 6.5% w/w, 5.5% w/w to about 6.5% w/w, or from about 6% w/w to about 6.5% w/w. In some embodiments, the third silicone excipient blend is present at about 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


In further embodiments, the third silicone excipient blend includes polydimethylcyclosiloxanes. Polydiemthylcyclosiloxanes are cyclic dimethicones including multiple monomer [SiO(CH3)2] units. A non-limiting example of a silicone excipient blend including polydimethylcyclosiloxanes is ST-Cyclomethicone®5-NF. ST-Cyclomethicone®5-NF is a clear, colorless, volatile polydimethylcyclosiloxane composed mainly of decamethylcyclopentasiloxane. In some embodiments, the third silicone excipient blend is present from about 10% w/w to about 30% w/w. In some embodiments, the third silicone excipient blend is present from about 12% w/w to about 30% w/w, from about 14% w/w to about 30% w/w, from about 16% w/w to about 30% w/w, from about 18% w/w to about 30% w/w, from about 20% w/w to about 30% w/w, from about 22% w/w to about 30% w/w, from about 24% w/w to about 30% w/w, from about 26% w/w to about 30% w/w, from about 28% w/w to about 30% w/w, from about 12% w/w to about 28% w/w, from about 14% w/w to about 28% w/w, from about 16% w/w to about 28% w/w, from about 18% w/w to about 28% w/w, from about 20% w/w to about 28% w/w, from about 22% w/w to about 28% w/w, from about 24% w/w to about 28% w/w, from about 26% w/w to about 28% w/w, from about 12% w/w to about 26% w/w, from about 14% w/w to about 26% w/w, from about 16% w/w to about 26% w/w, from about 18% w/w to about 26% w/w, from about 20% w/w to about 26% w/w, from about 22% w/w to about 26% w/w, from about 24% w/w to about 26% w/w, from about 12% w/w to about 24% w/w, from about 14% w/w to about 24% w/w, from about 16% w/w to about 24% w/w, from about 18% w/w to about 24% w/w, from about 20% w/w to about 24% w/w, from about 22% w/w to about 24% w/w, from about 12% w/w to about 22% w/w, from about 14% w/w to about 22% w/w, from about 16% w/w to about 22% w/w, from about 18% w/w to about 22% w/w, from about 20% w/w to about 22% w/w, from about 12% w/w to about 20% w/w, from about 14% w/w to about 20% w/w, from about 16% w/w to about 20% w/w, from about 18% w/w to about 20% w/w, from about 12% w/w to about 18% w/w, from about 14% w/w to about 18% w/w, from about 16% w/w to about 18% w/w, from about 12% w/w to about 16% w/w, from about 14% w/w to about 16% w/w, or from about 12% w/w to about 14% w/w. In some embodiments, the third silicone excipient blend is present at about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w). The third silicone excipient may be present in a quantity sufficient (q.s.) such that the total of all components (i.e. active pharmaceutical ingredients, silicone excipient blends, and lipid excipients) present in a non-aqueous composition equals 100% w/w. For example where the total of active pharmaceutical ingredients, silicone excipient blends, and lipid excipients in a non-aqueous composition is 36.35%, the amount of the third silicone excipient is 63.65% w/w thereby resulting in a total of 100% w/w for all components present in the non-aqueous composition.


The silicone excipient blend according to the embodiments provided herein may include a silicone compound and an acceptable silicone excipient blend carrier. Where the silicone excipient blend includes a silicone compound and an acceptable silicone excipient blend carrier, the silicone compound is combined with an agent which is not a silicone compound. Examples for acceptable silicone excipient blend carriers are stearyl alcohol, isostearyl alcohol, and 1-dodecene. Thus, a silicone excipient blend as provided herein may include one silicone compound. In some embodiments, the fourth silicone excipient blend includes alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. Alkylmethyl siloxane copolyol is a branched dimethiconol modified with alkyl and polyether groups also known as lauryl PEG-9 polydimethylsiloxyethyl dimethicone. A non-limiting example of a silicone excipient blend including alkylmethyl siloxane copolyol is Emulsifier®10. Emulsifier®10 is a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. In some embodiments, the fourth silicone excipient blend is present from about 2% w/w to about 5% w/w. In some embodiments, the fourth silicone excipient blend is present from about 2.2% w/w to about 5% w/w, from about 2.4% w/w to about 5% w/w, from about 2.6% w/w to about 5% w/w, from about 2.8% w/w to about 5% w/w, from about 3% w/w to about 5% w/w, from about 3.2% w/w to about 5% w/w, from about 3.4% w/w to about 5% w/w, from about 3.6% w/w to about 5% w/w, from about 3.8% w/w to about 5% w/w, from about 4% w/w to about 5% w/w, from about 4.2% w/w to about 5% w/w, from about 4.4% w/w to about 5% w/w, from about 4.6% w/w to about 5% w/w, from about 4.8% w/w to about 5% w/w, 2.2% w/w to about 4.8% w/w, from about 2.4% w/w to about 4.8% w/w, from about 2.6% w/w to about 4.8% w/w, from about 2.8% w/w to about 4.8% w/w, from about 3% w/w to about 4.8% w/w, from about 3.2% w/w to about 4.8% w/w, from about 3.4% w/w to about 4.8% w/w, from about 3.6% w/w to about 4.8% w/w, from about 3.8% w/w to about 4.8% w/w, from about 4% w/w to about 4.8% w/w, from about 4.2% w/w to about 4.8% w/w, from about 4.4% w/w to about 4.8% w/w, from about 4.6% w/w to about 4.8% w/w, 2.2% w/w to about 4.6% w/w, from about 2.4% w/w to about 4.6% w/w, from about 2.6% w/w to about 4.6% w/w, from about 2.8% w/w to about 4.6% w/w, from about 3% w/w to about 4.6% w/w, from about 3.2% w/w to about 4.6% w/w, from about 3.4% w/w to about 4.6% w/w, from about 3.6% w/w to about 4.6% w/w, from about 3.8% w/w to about 4.6% w/w, from about 4% w/w to about 4.6% w/w, from about 4.2% w/w to about 4.6% w/w, from about 4.4% w/w to about 4.6% w/w, 2.2% w/w to about 4.4 w/w, from about 2.4% w/w to about 4.4% w/w, from about 2.6% w/w to about 4.4% w/w, from about 2.8% w/w to about 4.4% w/w, from about 3% w/w to about 4.4% w/w, from about 3.2% w/w to about 4.4% w/w, from about 3.4% w/w to about 4.4% w/w, from about 3.6% w/w to about 4.4% w/w, from about 3.8% w/w to about 4.4% w/w, from about 4% w/w to about 4.4% w/w, from about 4.2% w/w to about 4.4% w/w, 2.2% w/w to about 4.2w/w, from about 2.4% w/w to about 4.2% w/w, from about 2.6% w/w to about 4.2% w/w, from about 2.8% w/w to about 4.2% w/w, from about 3% w/w to about 4.2% w/w, from about 3.2% w/w to about 4.2% w/w, from about 3.4% w/w to about 4.2% w/w, from about 3.6% w/w to about 4.2% w/w, from about 3.8% w/w to about 4.2% w/w, from about 4% w/w to about 4.2% w/w, 2.2% w/w to about 4%/w, from about 2.4% w/w to about 4% w/w, from about 2.6% w/w to about 4% w/w, from about 2.8% w/w to about 4% w/w, from about 3% w/w to about 4% w/w, from about 3.2% w/w to about 4% w/w, from about 3.4% w/w to about 4% w/w, from about 3.6% w/w to about 4% w/w, from about 3.8% w/w to about 4% w/w, 2.2% w/w to about 3.8% w/w, from about 2.4% w/w to about 3.8% w/w, from about 2.6% w/w to about 3.8% w/w, from about 2.8% w/w to about 3.8% w/w, from about 3% w/w to about 3.8% w/w, from about 3.2% w/w to about 3.8% w/w, from about 3.4% w/w to about 3.8% w/w, from about 3.6% w/w to about 3.8% w/w, 2.2% w/w to about 3.6% w/w, from about 2.4% w/w to about 3.6% w/w, from about 2.6% w/w to about 3.6% w/w, from about 2.8% w/w to about 3.6% w/w, from about 3% w/w to about 3.6% w/w, from about 3.2% w/w to about 3.6% w/w, from about 3.4% w/w to about 3.6% w/w, 2.2% w/w to about 3.4% w/w, from about 2.4% w/w to about 3.4% w/w, from about 2.6% w/w to about 3.4% w/w, from about 2.8% w/w to about 3.4% w/w, from about 3% w/w to about 3.4% w/w, from about 3.2% w/w to about 3.4% w/w, 2.2% w/w to about 3.2% w/w, from about 2.4% w/w to about 3.2% w/w, from about 2.6% w/w to about 3.2% w/w, from about 2.8% w/w to about 3.2% w/w, from about 3% w/w to about 3.2% w/w, 2.2% w/w to about 3% w/w, from about 2.4% w/w to about 3% w/w, from about 2.6% w/w to about 3% w/w, from about 2.8% w/w to about 3% w/w, 2.2% w/w to about 2.8% w/w, from about 2.4% w/w to about 2.8% w/w, from about 2.6% w/w to about 2.8% w/w, 2.2% w/w to about 2.6% w/w, from about 2.4% w/w to about 2.6% w/w, or 2.2% w/w to about 2.4% w/w. In some embodiments, the fourth silicone excipient blend is present at about 2, 2.2, 2.4, 2.6, 2.8, 3, 3.2, 3.4, 3.6, 3.8, 4, 4.2, 4.4, 4.6, 4.8 or 5% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


The silicone excipient blend according to yet more embodiments provided herein may include a silicone compound and an acceptable silicone excipient blend carrier. Where the silicone excipient blend includes a silicone compound and an acceptable silicone excipient blend carrier, the silicone compound is combined with an agent which is not a silicone compound. Examples for acceptable silicone excipient blend carriers are stearyl alcohol, isostearyl alcohol, and 1-dodecene. Thus, a silicone excipient blend as provided herein may include one silicone compound. In some embodiments, the fourth silicone excipient blend includes alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. Alkylmethyl siloxane copolyol is a branched dimethiconol modified with alkyl and polyether groups also known as lauryl PEG-9 polydimethylsiloxyethyl dimethicone. A non-limiting example of a silicone excipient blend including alkylmethyl siloxane copolyol is Emulsifier®10. Emulsifier®10 is a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. In some embodiments, the fourth silicone excipient blend is present from about 0.5% w/w to about 5% w/w. In some embodiments, the fourth silicone excipient blend is present from about 1% w/w to about 5% w/w, from about 1.5% w/w to about 5% w/w, from about 2% w/w to about 5% w/w, from about 2.5% w/w to about 5% w/w, from about 3% w/w to about 5% w/w, from about 3.5% w/w to about 5% w/w, from about 4% w/w to about 5% w/w, from about 4.5% w/w to about 5% w/w, from about 1% w/w to about 4.5% w/w, from about 1.5% w/w to about 4.5% w/w, from about 2% w/w to about 4.5% w/w, from about 2.5% w/w to about 4.5% w/w, from about 3% w/w to about 4.5% w/w, from about 3.5% w/w to about 4.5% w/w, from about 4% w/w to about 4.5% w/w, from about 1% w/w to about 4% w/w, from about 1.5% w/w to about 4% w/w, from about 2% w/w to about 4% w/w, from about 2.5% w/w to about 4% w/w, from about 3% w/w to about 4% w/w, from about 3.5% w/w to about 4% w/w, from about 1% w/w to about 3.5% w/w, from about 1.5% w/w to about 3.5% w/w, from about 2% w/w to about 3.5% w/w, from about 2.5% w/w to about 3.5% w/w, from about 3% w/w to about 3.5% w/w, from about 1% w/w to about 3% w/w, from about 1.5% w/w to about 3% w/w, from about 2% w/w to about 3% w/w, from about 2.5% w/w to about 3% w/w, from about 1% w/w to about 2.5% w/w, from about 1.5% w/w to about 2.5% w/w, from about 2% w/w to about 2.5% w/w, from about 1% w/w to about 2% w/w, from about 1.5% w/w to about 2% w/w, or from about 1% w/w to about 1.5% w/w. In some embodiments, the fourth silicone excipient blend is present at about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


In some embodiments, the fifth silicone excipient blend includes stearyloxytrimethylsilane and stearyl alcohol. Stearyloxytrimethylsilane refers, in the customary sense, to CAS Registry No. 18748-98-6 and stearyl alcohol refers, in the customary sense, to CAS Registry Number No. 112-92-5. A non-limiting example of a silicone excipient blend including stearyloxytrimethylsilane and stearyl alcohol is Silky Wax®10. Silky Wax®10 is a soft, solid mixture of stearyloxytrimethylsilane and stearyl alcohol. In some embodiments, the fifth silicone excipient blend is present from about 5% w/w. In some embodiments, the fifth silicone excipient blend is present from about 1% w/w to about 10% w/w, from about 2% w/w to about 10% w/w, from about 3% w/w to about 10% w/w, from about 4% w/w to about 10% w/w, from about 5% w/w to about 10% w/w, from about 6% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 1% w/w to about 9% w/w, from about 2% w/w to about 9% w/w, from about 3% w/w to about 9% w/w, from about 4% w/w to about 9% w/w, from about 5% w/w to about 9% w/w, from about 6% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 1% w/w to about 8% w/w, from about 2% w/w to about 8% w/w, from about 3% w/w to about 8% w/w, from about 4% w/w to about 8% w/w, from about 5% w/w to about 8% w/w, from about 6% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, from about 1% w/w to about 7% w/w, from about 2% w/w to about 7% w/w, from about 3% w/w to about 7% w/w, from about 4% w/w to about 7% w/w, from about 5% w/w to about 7% w/w, from about 6% w/w to about 7% w/w, from about 1% w/w to about 6% w/w, from about 2% w/w to about 6% w/w, from about 3% w/w to about 6% w/w, from about 4% w/w to about 6% w/w, from about 5% w/w to about 6% w/w, from about 1% w/w to about 5% w/w, from about 2% w/w to about 5% w/w, from about 3% w/w to about 5% w/w, from about 4% w/w to about 5% w/w, from about 1% w/w to about 4% w/w, from about 2% w/w to about 4% w/w, from about 3% w/w to about 4% w/w, from about 1% w/w to about 3% w/w, from about 2% w/w to about 3% w/w, or from about 1% w/w to about 2% w/w. In some embodiments, the fifth silicone excipient blend is present at about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


In further embodiments, the fifth silicone excipient blend includes stearyloxytrimethylsilane and stearyl alcohol. Stearyloxytrimethylsilane refers, in the customary sense, to CAS Registry No. 18748-98-6 and stearyl alcohol refers, in the customary sense, to CAS Registry Number No. 112-92-5. A non-limiting example of a silicone excipient blend including stearyloxytrimethylsilane and stearyl alcohol is Silky Wax®10. Silky Wax®10 is a soft, solid mixture of stearyloxytrimethylsilane and stearyl alcohol. In some embodiments, the fifth silicone excipient blend is present from about 5% w/w to about 15% w/w. In some embodiments, the fifth silicone excipient blend is present from about 6% w/w to about 15% w/w, from about 7% w/w to about 15% w/w, from about 8% w/w to about 15% w/w, from about 9% w/w to about 15% w/w, from about 10% w/w to about 15% w/w, from about 11% w/w to about 15% w/w, from about 12% w/w to about 15% w/w, from about 13% w/w to about 15% w/w, from about 14% w/w to about 15% w/w, from about 6% w/w to about 14% w/w, from about 7% w/w to about 14% w/w, from about 8% w/w to about 14% w/w, from about 9% w/w to about 14% w/w, from about 10% w/w to about 14% w/w, from about 11% w/w to about 14% w/w, from about 12% w/w to about 14% w/w, from about 13% w/w to about 14% w/w, from about 6% w/w to about 13% w/w, from about 7% w/w to about 13% w/w, from about 8% w/w to about 13% w/w, from about 9% w/w to about 13% w/w, from about 10% w/w to about 13% w/w, from about 11% w/w to about 13% w/w, from about 12% w/w to about 13% w/w, from about 6% w/w to about 12% w/w, from about 7% w/w to about 12% w/w, from about 8% w/w to about 12% w/w, from about 9% w/w to about 12% w/w, from about 10% w/w to about 12% w/w, from about 11% w/w to about 12% w/w, from about 6% w/w to about 11% w/w, from about 7% w/w to about 11% w/w, from about 8% w/w to about 11% w/w, from about 9% w/w to about 11% w/w, from about 10% w/w to about 11% w/w, from about 6% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 6% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 6% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, or from about 6% w/w to about 7% w/w. In some embodiments, the fifth silicone excipient blend is present at about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


In other embodiments, the sixth silicone excipient blend includes dimethiconol and hexamethyldisiloxane. Dimethiconol refers, in the customary sense, to CAS Registry No. 70131-67 and hexamethyldisiloxane, in the customary sense, to CAS Registry Number No. 107-46-0. A non-limiting example of a silicone excipient blend including is dimethiconol in hexamethyldisiloxane Silmogen Carrier®. Silmogen Carrier® is a blend of approximately 1% of an ultra high viscosity dimethiconol in a volatile silicone fluid (hexamethyldisiloxane). In some embodiments, the sixth silicone excipient blend is present from about 5% w/w to about 10% w/w. In some embodiments, the sixth silicone excipient blend is present from about 5.5% w/w to about 10% w/w, from about 6% w/w to about 10% w/w, from about 6.5% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 7.5% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 8.5% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 9.5% w/w to about 10% w/w, from about 5% w/w to about 9.5% w/w, 5.5% w/w to about 9.5% w/w, from about 6% w/w to about 9.5% w/w, from about 6.5% w/w to about 9.5% w/w, from about 7% w/w to about 9.5% w/w, from about 7.5% w/w to about 9.5% w/w, from about 8% w/w to about 9.5% w/w, from about 8.5% w/w to about 9.5% w/w, from about 9% w/w to about 9.5% w/w, from about 5% w/w to about 9% w/w, 5.5% w/w to about 9% w/w, from about 6% w/w to about 9% w/w, from about 6.5% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 7.5% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 8.5% w/w to about 9% w/w, from about 5% w/w to about 8.5% w/w, 5.5% w/w to about 8.5% w/w, from about 6% w/w to about 8.5% w/w, from about 6.5% w/w to about 8.5% w/w, from about 7% w/w to about 8.5% w/w, from about 7.5% w/w to about 8.5% w/w, from about 8% w/w to about 8.5% w/w, from about 5% w/w to about 8% w/w, 5.5% w/w to about 8% w/w, from about 6% w/w to about 8% w/w, from about 6.5% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, from about 7.5% w/w to about 8% w/w, from about 5% w/w to about 7.5% w/w, 5.5% w/w to about 7.5% w/w, from about 6% w/w to about 7.5% w/w, from about 6.5% w/w to about 7.5% w/w, from about 7% w/w to about 7.5% w/w, from about 5% w/w to about 7% w/w, 5.5% w/w to about 7% w/w, from about 6% w/w to about 7% w/w, from about 6.5% w/w to about 7% w/w, from about 5% w/w to about 6.5% w/w, 5.5% w/w to about 6.5% w/w, or from about 6% w/w to about 6.5% w/w. The numerical values above represent amounts of silicone excipient in % (w/w). In some embodiments, the sixth silicone excipient blend is present at about 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10% (w/w). The sixth silicone excipient may be present in a quantity sufficient (q.s.) that the total of all components (i.e. active pharmaceutical ingredients, silicone excipient blends, and lipid excipients) present in a non-aqueous composition equals 100% w/w. For example where the total of active pharmaceutical ingredients, silicone excipient blends, and lipid excipients in a non-aqueous composition is 36.35%, the amount of the sixth silicone excipient is 63.65% w/w thereby resulting in a total of 100% w/w for all components present in the non-aqueous composition.


In other embodiments, the seventh silicone excipient blend includes alkylmethyl siloxane wax. Alkylmethyl siloxane wax refers to a C30-45 alkyl methicone. A non-limiting example of a silicone excipient blend including alkylmethyl siloxane wax is ST-Wax®30. ST-Wax®30 is an occlusive siloxane wax which can be used t replace occlusive organic excipients in ointments, emulsions or stick formulations. In some embodiments, the seventh silicone excipient blend is present from about 5% w/w to about 15% w/w. In some embodiments, the seventh silicone excipient blend is present from about 6% w/w to about 15% w/w, from about 7% w/w to about 15% w/w, from about 8% w/w to about 15% w/w, from about 9% w/w to about 15% w/w, from about 10% w/w to about 15% w/w, from about 11% w/w to about 15% w/w, from about 12% w/w to about 15% w/w, from about 13% w/w to about 15% w/w, from about 14% w/w to about 15% w/w, from about 6% w/w to about 14% w/w, from about 7% w/w to about 14% w/w, from about 8% w/w to about 14% w/w, from about 9% w/w to about 14% w/w, from about 10% w/w to about 14% w/w, from about 11% w/w to about 14% w/w, from about 12% w/w to about 14% w/w, from about 13% w/w to about 14% w/w, from about 6% w/w to about 13% w/w, from about 7% w/w to about 13% w/w, from about 8% w/w to about 13% w/w, from about 9% w/w to about 13% w/w, from about 10% w/w to about 13% w/w, from about 11% w/w to about 13% w/w, from about 12% w/w to about 13% w/w, from about 6% w/w to about 12% w/w, from about 7% w/w to about 12% w/w, from about 8% w/w to about 12% w/w, from about 9% w/w to about 12% w/w, from about 10% w/w to about 12% w/w, from about 11% w/w to about 12% w/w, from about 6% w/w to about 11% w/w, from about 7% w/w to about 11% w/w, from about 8% w/w to about 11% w/w, from about 9% w/w to about 11% w/w, from about 10% w/w to about 11% w/w, from about 6% w/w to about 10% w/w, from about 7% w/w to about 10% w/w, from about 8% w/w to about 10% w/w, from about 9% w/w to about 10% w/w, from about 6% w/w to about 9% w/w, from about 7% w/w to about 9% w/w, from about 8% w/w to about 9% w/w, from about 6% w/w to about 8% w/w, from about 7% w/w to about 8% w/w, or from about 6% w/w to about 7% w/w. In some embodiments, the seventh silicone excipient blend is present at about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15% (w/w). The numerical values above represent amounts of silicone excipient in % (w/w).


Table 1-5 describe various examples of combinations of effective amounts of silicone excipient blends useful in the methods, products and compositions provided herein. In particular, Table 1 provides 121 different combinations of concentrations of Elastomer®10, as shown in the first column labeled “Elastomer®10”, and Dimethiconol Blend®20, as shown in the first row labeled “Dimethiconol Blend®20.” Specific concentrations of Elastomer®10 and Dimethiconol Blend®20 for each of the combinations described in Table 1 and numbered from 1 to 121 are shown, respectively, in the cells in the first column and in the first row, which correspond to the numbered cell.


Table 2 provides 297 different combinations of concentrations of Cyclomethicone, as shown in the first column labeled “Cyclomethicone”, and Emulsifier®10, as shown in the first row labeled “Emulsifier®10.” Specific concentrations of Cyclomethicone and Emulsifier®10 for each of the combinations described in Table 2 and numbered from 122 to 297 are shown, respectively, in the cells in the first column and in the first row, which correspond to the numbered cell.


The compositions and products provided herein include combinations of Elastomer®10, Dimethiconol Blend®20, Cyclomethicone, and Emulsifier®10, respectively. Each of the 121 combinations of concentrations in Table 1 may be combined with any of the 297 combinations of concentrations of Table 2, resulting in 35,937 possible combinations of concentrations. Therefore, 35,937 individual combination products of Elastomer®10, Dimethiconol Blend®20, Cyclomethicone, and Emulsifier®10 are specifically disclosed in Tables 1 and 2, and are useful in the compositions, products and methods provided herein.


Table 3 provides 156 different combinations of concentrations of Elastomer®10, as shown in the first column labeled “Elastomer®10”, and Dimethiconol Blend®20, as shown in the first row labeled “Dimethiconol Blend®20.” Specific concentrations of Elastomer®10 and Dimethiconol Blend®20 for each of the combinations described in Table 3 and numbered from 1 to 156 are shown, respectively, in the cells in the first column and in the first row, which correspond to the numbered cell.


Table 4 provides 335 different combinations of concentrations of Cyclomethicone, as shown in the first column labeled “Cyclomethicone”, and Elastomer®10, as shown in the first row labeled “Elastomer®10.” Specific concentrations of Cyclomethicone and Elastomer®10 for each of the combinations described in Table 4 and numbered from 157 to 492 are shown, respectively, in the cells in the first column and in the first row, which correspond to the numbered cell.


Table 5 provides 109 different combinations of concentrations of ST-Wax®30, as shown in the first column labeled “ST-Wax®30”, and Dimethiconol Blend®20, as shown in the first row labeled “Dimethiconol Blend®20.” Specific concentrations of ST-Wax®30 and Dimethiconol Blend®20 for each of the combinations described in Table 5 and numbered from 493 to 602 are shown, respectively, in the cells in the first column and in the first row, which correspond to the numbered cell.


The compositions and products provided herein include combinations of Elastomer®10, Dimethiconol Blend®20, Cyclomethicone, and ST-Wax®30, respectively. Each of the 156 combinations of concentrations in Table 3 may be combined with any of the 335 combinations of concentrations of Table 4 and/or any of the 109 combinations of Table 5, resulting in 52,260 (combination of concentrations in Table 3 and 4), 17,004 (combination of concentrations in Table 3 and 5) or 5,696,340 (combination of concentrations of Table 3, 4, and 5) possible combinations of concentrations. Therefore, 5,696,340 individual combination products of Elastomer®10, Dimethiconol Blend®20, Cyclomethicone, and ST-Wax®30 are specifically disclosed in Tables 3-5, and are useful in the compositions, products and methods provided herein. Further, it is also noted that the individual combinations encompassed in of all of Tables 1-5 are possible as well.









TABLE 1







Effective Amounts of Elastomer ®10 and Dimethiconol Blend ®20








Elastomer 10 ®
Dimethiconol Blend ®20 w/w


















w/w
5%
5.50%
6%
6.50%
7%
7.50%
8%
8.50%
9%
9.50%
10%





















  5%
1
12
23
34
45
56
67
78
89
100
111


5.50%
2
13
24
35
46
57
68
79
90
101
112


  6%
3
14
25
36
47
58
69
80
91
102
113


6.50%
4
15
26
37
48
59
70
81
92
103
114


  7%
5
16
27
38
49
60
71
82
93
104
115


7.50%
6
17
28
39
50
61
72
83
94
105
116


  8%
7
18
29
40
51
62
73
84
95
106
117


8.50%
8
19
30
41
52
63
74
85
96
107
118


  9%
9
20
31
42
53
64
75
86
97
108
119


9.50%
10
21
32
43
54
65
76
87
98
109
120



10%

11
22
33
44
55
66
77
88
99
110
121
















TABLE 2







Effective Amounts of Cyclomethicone and Emulsifier ®10








Cyclometh-
Emulsifier ®10























icone
2%
2.20%
2%
2.60%
3%
3.00%
3%
3.40%
4%
3.80%
4%
4.20%
4%
4.60%
5%
5.00%


























  5%
122
133
144
155
166
177
188
199
210
221
232
243
254
265
276
287


5.50%
123
134
145
156
167
178
189
200
211
222
233
244
255
266
277
288


  6%
124
135
146
157
168
179
190
201
212
223
234
245
256
267
278
289


6.50%
125
136
147
158
169
180
191
202
213
224
235
246
257
268
279
290


  7%
126
137
148
159
170
181
192
203
214
225
236
247
258
269
280
291


7.50%
127
138
149
160
171
182
193
204
215
226
237
248
259
270
281
292


  8%
128
139
150
161
172
183
194
205
216
227
238
249
260
271
282
293


8.50%
129
140
151
162
173
184
195
206
217
228
239
250
261
272
283
294


  9%
130
141
152
163
174
185
196
207
218
229
240
251
262
273
284
295


9.50%
131
142
153
164
175
186
197
208
219
230
241
252
263
274
285
296



10%

132
143
154
165
176
187
198
209
220
231
242
253
264
275
286
297
















TABLE 3







Effective Amounts of Elastomer ®10 and Dimethiconol Blend ®20








Elastomer ®10
Dimethiconol Blend ®20 w/w

















w/w
1%
2.00%
3%
4.00%
5%
6.00%
7%
8.00%
9%
10.00%




















   5%
1
13
29
45
61
77
93
109
125
141


 6.00%
2
14
30
46
62
78
94
110
126
142


   7%
3
15
31
47
63
79
95
111
127
143


 8.00%
4
16
32
48
64
80
96
112
128
144


   9%
5
17
33
49
65
81
97
113
129
145


10.00%
6
18
34
50
66
82
98
114
130
146


  11%
7
19
35
51
67
83
99
115
131
147


12.00%
8
20
36
52
68
84
100
116
132
148


  13%
9
21
37
53
69
85
101
117
133
149


14.00%
10
22
38
54
70
86
102
118
134
150


  15%
11
23
39
55
71
87
103
119
135
151


16.00%
12
24
40
56
72
88
104
120
136
152


  17%
13
25
41
57
73
89
105
121
137
153


18.00%
14
26
42
58
74
90
106
122
138
154


  19%
15
27
43
59
75
91
107
123
139
155


20.00%
16
28
44
60
76
92
108
124
140
156
















TABLE 4







Effective Amounts of Cyclomethicone and Elastomer ®10








Cyclometh-
Elastomer ®10 w/w























icone w/w
5%
6.00%
7%
8.00%
9%
10.00%
11%
12.00%
13%
14.00%
15%
16.00%
17%
18.00%
19%
20.00%


























10%
157
178
199
220
241
262
283
304
325
346
367
388
409
430
451
472


11.00%  
158
179
200
221
242
263
284
305
326
347
368
389
410
431
452
473


12%
159
180
201
222
243
264
285
306
327
348
369
390
411
432
453
474


13.00%  
160
181
202
223
244
265
286
307
328
349
370
391
412
433
454
475


14%
161
182
203
224
245
266
287
308
329
350
371
392
413
434
455
476


15.00%  
162
183
204
225
246
267
288
309
330
351
372
393
414
435
456
477


16%
163
184
205
226
247
268
289
310
331
352
373
394
415
436
457
478


17.00%  
164
185
206
227
248
269
290
311
332
353
374
395
416
437
458
479


18%
165
186
207
228
249
270
291
312
333
354
375
396
417
438
459
480


19.00%  
166
187
208
229
250
271
292
313
334
355
376
397
418
439
460
481


20%
167
188
209
230
251
272
293
314
335
356
377
398
419
440
461
482


21.00%  
168
189
210
231
252
273
294
315
336
357
378
399
420
441
462
483


22%
169
190
211
232
253
274
295
316
337
358
379
400
421
442
463
484


23.00%  
170
191
212
233
254
275
296
317
338
359
380
401
422
443
464
485


24%
171
192
213
234
255
276
297
318
339
360
381
402
423
444
465
486


25.00%  
172
193
214
235
256
277
298
319
340
361
382
403
424
445
466
487


26%
173
194
215
236
257
278
299
320
341
362
383
404
425
446
467
488


27.00%  
174
195
216
237
258
279
300
321
342
363
384
405
426
447
468
489


28%
175
196
217
238
259
280
301
322
343
364
385
406
427
448
469
490


29.00%  
176
197
218
239
260
281
302
323
344
365
386
407
428
449
470
491


30%
177
198
219
240
261
282
303
324
345
366
387
408
429
450
471
492
















TABLE 5







Effective Amounts of ST Wax ®30 and Dimethiconol Blend ®20








ST Wax ®30
Dimethiconol Blend ®20 w/w

















w/w
1%
2.00%
3%
4.00%
5%
6.00%
7%
8.00%
9%
10.00%




















   5%
493
504
515
526
537
548
559
570
581
592


 6.00%
494
505
516
527
538
549
560
571
582
593


   7%
495
506
517
528
539
550
561
572
583
594


 8.00%
496
507
518
529
540
551
562
573
584
595


   9%
497
508
519
530
541
552
563
574
585
596


10.00%
498
509
520
531
542
553
564
575
586
597


  11%
499
510
521
532
543
554
565
576
587
598


12.00%
500
511
522
533
544
555
566
577
588
599


  13%
501
512
523
534
545
556
567
578
589
600


14.00%
502
513
524
535
546
557
568
579
590
601


  15%
503
514
525
536
547
558
569
580
591
602









The compositions and products according to the embodiments of the present invention may include a salt, a tonicity agent, a lipid excipient or a thickening agent. Thus, in some embodiments, the composition further includes a salt, a tonicity agent, a lipid excipient or a thickening agent. In other embodiments, the composition includes a salt, a tonicity agent, a lipid excipient and a thickening agent.


The non-aqueous compositions and products according to the embodiments of the present invention may include a lipid excipient or a thickening agent. Thus, in some embodiments, the composition further includes a lipid excipient or a thickening agent. In other embodiments, the composition includes a lipid excipient and a thickening agent. The non-aqueous compositions as provided herein may include at least one lipid excipient. Thus, in some embodiments, the composition includes a plurality of lipid excipients. In some embodiments, the composition includes a plurality of lipid excipients or a thickening agent. In other embodiments, the composition includes a plurality of lipid excipients and a thickening agent. Where the no-aqueous composition includes a plurality of lipid excipients it includes more than one lipid excipient.


In some embodiments, the salt is sodium chloride. In other embodiments, the salt is sodium hydroxide. In some further embodiments, the salt is present from about 0.5% w/w to about 1% w/w.


The term “tonicity agent” as used herein refers to a compound or ion useful for adjusting the osmotic pressure or tension of a solution, often relative to that of blood. Examples for tonicity agents are without limitation, glycerin, erythritol, mannitol, potassium, chloride, and sodium chloride. In some embodiments, the tonicity agent is glycerin. In some further embodiments, the tonicity agent is present from about 0.5% w/w to about 6% w/w.


The term “lipid excipient” as used herein refers to a lipid-based material that is co-formulated with a pharmaceutical composition. Non-limiting examples include castor oil, linoleic acid, bisabolol, squalane, propylene glycol, isostearyl isostearate, isopropyl myristate, diethylene glycol, dipropylene glycol, mineral oil, vegetable oil, almond oil, petrolatum, microcrystalline wax, lanolin, beeswax, caprylic/capric triglycerides, cetyl alcohol, mineral oil, jojoba seed oil, stearyl alcohol, arachidyl alcohol, behenyl alcohol, and long chain fatty acids (C12-C22). In some embodiments, the lipid excipient is mineral oil. In some further embodiments, the mineral oil is present from about 0.5% w/w to about 12% w/w. In other embodiments, the lipid excipient is capric/caprylic triglyceride. In some further embodiments, the capric/caprylic triglyceride is present from about 5% w/w to about 12% w/w. In yet more embodiments, the mineral oil is present from about 0.5% w/w to about 10% w/w. In other embodiments, the lipid excipient is capric/caprylic triglyceride. In some further embodiments, the capric/caprylic triglyceride is present from about 5% w/w to about 15% w/w. In some embodiments, the lipid excipient is beeswax. In some further embodiments, the beeswax is present from about 10% w/w to about 30% w/w. In some embodiments, the lipid excipient is lanolin. In some further embodiments, the lanolin is present from about 5% w/w to about 10% w/w. In some embodiments, the lipid excipient is cetyl alcohol. In some further embodiments, the cetyl alcohol is present from about 5% w/w to about 10% w/w. In some embodiments, the lipid excipient is castor oil. In some embodiments, the lipid excipient is isopropyl myristate. In some further embodiments, the isopropyl myristate is present from about 0.5% w/w to about 15% w/w. In some embodiments, the lipid excipient is petrolatum. Petrolatum refers, in the customary sense, to CAS Registry No. 8009-03-8. Petrolatum is a semi-solid mixture of hydrocarbons (with carbon numbers mainly higher than 25). In some embodiments, the lipid excipient is vegetable oil. In some further embodiments, the vegetable oil is present from about 0.5% w/w to about 5% w/w. In some embodiments, the lipid excipient is almond oil. In some further embodiments, the almond oil is present from about 0.5% w/w to about 5% w/w.


The formulation's viscosity is a factor that determines how well the formulation sticks to the skin or ophthalmic tissue or does not run off the skin or ophthalmic tissue when applied. The viscosity of the formulation can be optimized using one or more pharmaceutically acceptable thickening agents that do not significantly interact with the components of the formulation, do not significantly reduce flux of the formulation, and do not cause stinging or irritation. Non-limiting examples of suitable thickeners useful herein include cellulosic polymers, such as gum arabic, gum acacia, gum tragacanth, locust bean gum, guar gum, hydroxypropyl guar, xanthan gum, talc, cellulose gum, sclerotium gum, carageenan gum, karaya gum, cellulose gum, rosin, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxymethylcellulosf, hydroxypropylmethylcellulose, methylhydroxyethylcellulose, cetyl hydroxyethylcellulose, carboxymethylcellulose, corn starch, hydroxypropyl starch phosphate, distarch phosphate, distarch dimethylene urea, aluminum starch octenyl succinate, maltodextrin, dextran, poly(acrylamide), PEG-150 distearate, PEG-150/decyl alcohol/SMDI copolymer, PEG-150/stearyl alcohol/SMDI copolymer, PEG-180/Laureth-50/TMMG copolymer, Polyether 1, acrylic acid/acrylamidomethyl propane sulfonic acid copolymer, acrylate/C10-30 alkyl acrylate cross polymer, acrylate/beheneth-25 methacrylate copolymer, acrylate/steareth-20 methacrylate copolymer, acrylate/steareth-20 copolymer, acrylate/VA cross polymer, acrylic acid/acrylonitrogen copolymer, ammonium acryloyldimethyltaurate/beheneth-25 methacrylate copolymer, ammonium acryloyldimethyltaurate/VP copolymer, caprylic/capric triglyceride (and) sodium acrylate copolymer, PVM/MA decadiene cross polymer, alginic acid, propylene glycol alginate, dimethicone, silica dimethyl silylate, a dimethylacrylamide/acrylic acid/polystyrene ethyl methacrylate copolymer, derivatives thereof, and mixtures thereof. In some embodiments, the thickening agent is a carbomer. The term “carbomer” refers to cross linked polyacrylate polymers as known in the art and, for example, to Carbopol® 980 of Carbopol® 980 polymer, which are defined by CAS Registry Nos. 9063-87-0, 9003-01-4, or 600-07-7. The polyacrylate polymer may be, but is not limited to, poly-2-methylbutanoic acid, poly-prop-2-enoic acid, polyacrylic acid. In some further embodiments, the carbomer is present from about 0.5% w/w to about 1% w/w. In some embodiments, the thickening agent is a talc. In some further embodiments, the talc is present from about 2% w/w to about 5% w/w.


Any other non-toxic, inert and effective carrier or excipient may be used to formulate topical compositions and products according to embodiments of the present invention. Examples of such useful pharmaceutically acceptable excipients, carriers and diluents include water, physiological saline, Ringer's solution, dextrose solution, Hank's solution, DMSO, a carbomer, a polyacrylic polymer, glycerin, sodium hydroxide, sodium thiosulfate, propyl gallate, an alkyl paraben, purified water, and mixtures thereof. Other ingredients, which may optionally be included into the topical compositions and products according to embodiments of the present invention, include humectants, such as propylene glycol; solvents, such as alcohols, sun filters, such as titanium dioxide, zinc oxide, and calcium carbonate; and anti-microbial preservatives, such as methylparaben and propylparaben. An organic or inorganic base may also be included, such as sodium hydroxide, which is used to adjust the pH of the initial components and the final product. Generally, ophthalmically acceptable excipients commonly known in the fields of ophthalmology and cosmetology as useful in topical compositions, and any non-toxic, inert, and effective topical carriers, are contemplated as useful in the compositions and products according to the embodiments of the present invention.


Other ingredients, which may optionally be included into the topical non-aqueous compositions and products according to embodiments of the present invention, include humectants, such as propylene glycol; solvents, such as alcohols, sun filters, such as titanium dioxide, zinc oxide, and calcium carbonate; and anti-microbial preservatives, such as methylparaben and propylparaben. An organic or inorganic base may also be included, such as sodium hydroxide, which is used to adjust the pH of the initial components and the final product. Generally, ophthalmically acceptable excipients commonly known in the fields of ophthalmology and cosmetology as useful in topical compositions, and any non-toxic, inert, and effective topical carriers, are contemplated as useful in the compositions and products according to the embodiments of the present invention.


As described above, the compositions provided herein include an active pharmaceutical ingredient. In some embodiments, the composition includes cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. The effective amounts for each of the individual active pharmaceutical ingredient (e.g. cyclosporine, tacrolimus, phentolamine) are described herein. For example, cyclosporine may be present in an amount approximately equal to or less than about 0.4% w/w, tacrolimus may be present in an amount approximately equal to or less than about 0.1% w/w, phentolamine may be present in an amount approximately equal to or less than about 1% w/w, testosterone may be present in an amount approximately equal to or less than about 5% w/w, dihydrotestosterone may be present in an amount approximately equal to or less than about 5% w/w and testosterone propionate may be present in an amount approximately equal to or less than about 5% w/w. The compositions of the present invention include effective amounts of the active pharmaceutical ingredients as provided herein at the concentrations described for each active pharmaceutical ingredient.


In some embodiments, the composition consists essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a salt, a tonicity agent, a lipid excipient, a thickening agent, and a silicone excipient. Where the composition consist essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a salt, a tonicity agent, a lipid excipient, a thickening agent, and a silicone excipient, the compositions consists of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, and any suitable salt, tonicity agent, lipid excipient, thickening agent and silicone excipient.


In some embodiments, the non-aqueous composition consists essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a plurality of lipid excipients, and a silicone excipient. In some embodiments, the non-aqueous composition consists essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a plurality of lipid excipients; and a plurality of silicone excipients. Where the non-aqueous composition consists essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a plurality of lipid excipients, and a plurality of silicone excipients, the non-aqueous composition consists of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin and any suitable plurality of lipid excipients and silicone excipient or plurality of silicone excipients.


In some embodiments, the non-aqueous composition consists essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a plurality of lipid excipients, a thickening agent, and a silicone excipient. In some embodiments, the non-aqueous composition consists essentially of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin, a plurality of lipid excipients, a thickening agent, and a plurality of silicone excipients.


The ophthalmic pharmaceutical compositions provided herein may be administered in various ways e.g. a foam, a gel, a cream, jelly, solution, suspension, a spray (e.g., a solution), an ointment, ointment films, occlusive films, sustained release films, fast drying films, slow drying films, patches, semi solids or stick formulation comprising a semi-solid vehicle with a melting point near physiological temperature. Topical compositions and products according to embodiments of the present invention can be formulated as creams, which can be semi-solid emulsions of oil and water, and lotions, including suspensions of powdered material in water or alcohol base and water-based emulsions.


Topical compositions and products according to embodiments of the present invention can also be formulated as ointments, which are oleaginous and contain little if any water. The ophthalmic pharmaceutical non-aqueous compositions provided herein may be administered in various ways e.g. an emulsion, a foam, a gel, a cream, jelly, solution, suspension, a spray (e.g., a solution), an ointment, ointment films, occlusive films, sustained release films, fast drying films, slow drying films, patches, semi solids or stick formulation comprising a semi-solid vehicle with a melting point near physiological temperature. Topical compositions and products according to embodiments of the present invention can also be formulated as ointments, which are oleaginous and contain little if any water.


In some embodiments, the ophthalmic pharmaceutical formulation is an ointment formulation. Where the ophthalmic pharmaceutical formulation is an ointment formulation, the active pharmaceutical ingredient may be a cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosteron, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is an ointment formulation, the formulation may include a first silicone excipient blend and a second silicone excipient blend. Thus, in some further embodiments, the silicone excipient is a first silicone excipient blend or a second silicone excipient blend. In some embodiments, the first silicone excipient blend is a mixture of dimethicone and dimethiconol and the second silicone excipient blend is a mixture of alkylmethyl siloxane wax. In other embodiments, the first silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer, and the second silicone excipient blend is a mixture of polydimethylcyclopentasiloxanes. In other embodiments, the non-aqueous composition further includes a lipid excipient. In some embodiments, the lipid excipient is petrolatum.


In some embodiments, the ophthalmic pharmaceutical formulation is a cream formulation. Where the ophthalmic pharmaceutical formulation is a cream formulation, the active pharmaceutical ingredient may be of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is a cream formulation the silicone excipient may include a first silicone excipient blend of dimethicone and dimethiconol, a second silicone excipient blend of cyclopentasiloxane and a dimethicone cross polymer, a third silicone excipient blend of polydiemthylcyclopentasiloxane and a fourth silicone excipient blend of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. In a further embodiment, the silicone excipient is a first silicone blend, a second silicone blend, a third silicone blend and a fourth silicone blend. In a further embodiment, the composition includes a salt and a tonicity agent. In a further embodiment, the salt is sodium chloride. In still further embodiments, the tonicity agent is glycerin.


In other embodiments, the silicone excipient is a blend of cyclopentasiloxane and a dimethicone cross polymer. In a further embodiment, the composition includes a salt, a tonicity agent, and a lipid excipient. In a further embodiment, the salt is sodium chloride. In still further embodiments, the tonicity agent is glycerin. In still further embodiments, the lipid excipient is caprylic/capric triglyceride.


In some embodiments, the ophthalmic pharmaceutical formulation is a gel formulation. Where the ophthalmic pharmaceutical formulation is a gel formulation, the active pharmaceutical ingredient may be of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is a gel formulation the silicone excipient may include a blend of stearyloxytrimethylsilane and stearyl alcohol. In still further embodiments, the silicone excipient is a blend of stearyloxytrimethylsilane and stearyl alcohol. In a further embodiment, the composition includes a thickening agent, a salt, a tonicity agent, and a lipid excipient. In some further embodiments, the thickening agent is a carbomer. In some further embodiments, the salt is sodium hydroxide. In still some further embodiments, the tonicity agent is glycerin. In a further embodiment, the lipid excipient is mineral oil.


In some embodiments, the ophthalmic pharmaceutical formulation is a gel formulation. Where the ophthalmic pharmaceutical formulation is a gel formulation, the active pharmaceutical ingredient may be a cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosteron, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is a gel formulation the formulation may include a first silicone excipient blend and a second silicone excipient blend. Thus, in some further embodiments, the silicone excipient is a first silicone excipient blend or a second silicone excipient blend. In some embodiments, the first silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer and the second silicone excipient blend is a mixture of polydimethylcyclosiloxanes. In a further embodiment, the non-aqueous composition includes a lipid excipient. In some embodiments, the lipid excipient is isopropyl myristate.


In some embodiments, the ophthalmic pharmaceutical formulation is an emulsion formulation. In some further embodiments, the active pharmaceutical ingredient is of cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosterone, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. In some further embodiments, the silicone excipient is a blend of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. In a further embodiment, the composition includes a lipid excipient, a salt, and a tonicity agent. In some further embodiments, the lipid excipient is mineral oil. In further embodiments, the salt is sodium chloride. In still another embodiment, the tonicity agent is glycerin.


In some embodiments, the ophthalmic pharmaceutical formulation is an emulsion formulation. Where the ophthalmic pharmaceutical formulation is an emulsion formulation, the active pharmaceutical ingredient may be a cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosteron, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is an emulsion formulation, the formulation include a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. Thus, in some further embodiments, the silicone excipient is a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene. In some further embodiments, the non-aqueous composition includes a lipid excipient. In some further embodiments, the lipid excipient is mineral oil. Where the ophthalmic pharmaceutical formulation is an emulsion formulation the formulation may include a first silicone excipient blend and a second silicone excipient blend. Thus, in some embodiments, the silicone excipient is a first silicone excipient blend or a second silicone excipient blend. In some further embodiments, the first silicone excipient blend is a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene, and the second silicone excipient blend is a mixture of dimethicone and dimethiconol. In some further embodiments, the non-aqueous composition of includes a lipid excipient. In some further embodiment, the lipid excipient is vegetable oil. In still a further embodiment, the lipid excipient is almond oil.


In some embodiments, the ophthalmic pharmaceutical formulation is a spray formulation. Where the ophthalmic pharmaceutical formulation is a spray formulation, the active pharmaceutical ingredient may be a cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosteron, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is a spray formulation, the formulation may include a mixture of dimethiconol and hexamethyldisiloxane. Thus, in some further embodiments, the silicone excipient is a mixture of dimethiconol and hexamethyldisiloxane. In some further embodiments, the non-aqueous composition includes a thickening agent. In some further embodiments, the thickening agent is talc. Where the ophthalmic pharmaceutical formulation is a spray formulation the formulation may include a first silicone excipient blend and a second silicone excipient blend. Thus, in some embodiments, the silicone excipient is a first silicone excipient blend and a second silicone excipient blend. In some further embodiments, the first silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer and the second silicone excipient blend is a mixture of dimethiconol and hexamethyldisiloxane. In some other embodiments, the formulation includes a first silicone excipient blend, a second silicone excipient blend and a third silicone excipient blend. In some further embodiments, the first silicone excipient blend is a mixture of dimethicone and dimethiconol, the second silicone excipient blend is a mixture of cyclopentasiloxane and dimethicone cross polymer, and the third silicone excipient blend is a mixture of polydimethylcyclosiloxanes.


In some embodiments, the ophthalmic pharmaceutical formulation is a stick formulation. Where the ophthalmic pharmaceutical formulation is a stick formulation, the active pharmaceutical ingredient may be a cyclosporine, tacrolimus, phentolamine, testosterone, dihydrotestosteron, testosterone propionate, dexamethasone, prednisolone, an EP2 receptor agonist, brimonidine, pilocarpine, a prostaglandin analog, ketorolac, timolol, or gatifloxacin. Further, where the ophthalmic pharmaceutical formulation is a stick formulation the formulation may include alkylmethyl siloxane wax. Thus, in some further embodiments, the silicone excipient is a alkylmethyl siloxane wax. In some further embodiments, the non-aqueous composition includes a plurality of lipid excipients. Where the ophthalmic pharmaceutical formulation is a stick formulation the formulation may include a first silicone excipient blend and a second silicone excipient blend. Thus, in some embodiments, the silicone excipient is a first silicone excipient blend or a second silicone excipient blend. In some further embodiments, the first silicone excipient blend is a mixture of stearyloxytrimethylsilane and stearyl alcohol, and the second silicone excipient blend is a mixture of polydimethylcyclosiloxanes. In some further embodiments, the non-aqueous composition includes a plurality of lipid excipients.


III. Treatment Methods

Methods of treating an ophthalmic disease are provided, including methods of treating glaucoma. Some embodiments of the methods provided herein comprise applying an ophthalmic formulation described herein to the region on or around the eye, which can treat ophthalmic diseases by sustained administration of an effective amount of an active pharmaceutical ingredients and a silicone excipient to the ophthalmic tissue (i.e. conjunctiva, lacrimal tissue or cornea).


In one aspect, a method of treating an ophthalmic disease in a subject in need thereof is provided. The method includes administering to the subject an active pharmaceutical ingredient and a silicone excipient. The active pharmaceutical ingredients useful for the methods according to the embodiments of the present invention are described herein. The active pharmaceutical ingredients include at least one (e.g. one) immunosuppressant (e.g. cyclosporine), at least one (e.g. one) vasodilator agent (e.g. phentolamine), at least one (e.g. one) anti-inflammatory agent (e.g. testosterone), at least one (e.g. one) EP2 receptor agonist (e.g. a compound of Formula Ia), at least one (e.g. one) muscarinic receptor agonist (e.g. pilocarpine), at least one (e.g. one) prostaglandin analog (e.g. bimatoprost), at least one (e.g. one) vasoconstrictor agent (e.g. brimonidine, a compound of Formula (IVa)), or at least one (e.g. one) anti-infective agent (e.g. gatifloxacin).


The methods provided herein include administering a silicone excipient. Silicone excipients suitable for the methods of treating an ophthalmic disease are provided herein and include silicone excipient blends (e.g. a silicone excipient blend including dimethicone and dimethiconol or a cyclopentasiloxane and a dimethicone cross polymer) and combinations thereof. The silicone based excipients provided herein possess unexpectedly advantageous properties in comparison with the conventional ophthalmic excipients, since they are chemically and biologically inert, have low surface tension (i.e. good spreading characteristics of water), improve chemical stability of labile active pharmaceutical ingredients and enable the solubility of hydrophobic active pharmaceutical ingredients.


In some embodiments, the ophthalmic disease is central retinal vein occlusion. In other embodiments, the ophthalmic disease is branch retinal vein occlusion. In other embodiments, the ophthalmic disease is choroidal macular edema. In another embodiment, the ophthalmic disease is diabetic macular edema. In some embodiments, the ophthalmic disease is diabetic macular retinopathy. In other embodiments, the ophthalmic disease is uveitis. In some other embodiments, the ophthalmic disease is age related macular degeneration. In other embodiments, the ophthalmic disease is glaucoma. In some embodiments, the ophthalmic disease is ocular hypertension.


In another aspect, a method of improving vision in a subject in need thereof is provided. The method includes administering to the subject an active pharmaceutical ingredient and a silicone excipient.


IV. Examples

Embodiments of the present invention are further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be made to various other embodiments, modifications and equivalents, which, after reading the description provided herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention.


Example 1

Tables 6A-B illustrate examples of cream and ointment formulations according to certain embodiments of the present invention.












TABLE 6A










Delivery System












Cream
Cream











Quantity












% w/w
% w/w















Formulation contains




any one of the below



Active Ingredients
active ingredients







Cyclosporine
 0.01-0.1



Tacrolimus
 0.01-0.1



Phentolamine
0.001-1%



Testosterone
0.001-5%



DihydroTestosterone
0.001-5%



Testosterone
0.001-5%



propionate




Compound of
  0.001-0.1%



Formula (Ia)




Compound of
  0.0002-0.05%



Formula (IIa)












Excipients





Dimethiconol Blend
 5-10




20





Elastomer 10
 5-10
5-10



Cyclomethicone 5-
 5-10




NF





Emulsifier 10
2-5
2-5



Sodium Chloride
1
1



Glycerin
2-5
2-5



Caprylic/capric

 5-12



triglyceride





Water
q.s.100
q.s. 100


















TABLE 6B








Delivery System










Ointment
Ointment









Quantity










% w/w
% w/w












Formulation contains anyone of the


Active Ingredients
below active ingredients





Cyclosporine
 0.01-0.1


Tacrolimus
 0.01-0.1


Phentolamine
0.001-1%


Testosterone
0.001-5%


Dihydro Testosterone
0.001-5%


Testosterone propionate
0.001-5%


Compound of Formula (Ia)
  0.001-0.1%


Compound of Formula (IIa)
  0.0002-0.05%









Excipients




ST-Wax 30

5-15


Dimethiconol Blend 20

5-10


Elastomer 10
10-20



Cyclomethicone 5-NF
10-20



Petrolatum
q.s. 100
q.s. 100









Example 2

Tables 7A-B illustrate examples of gel formulations according to certain embodiments of the present invention.












TABLE 7A










Delivery System












Gel
Gel











Quantity












% w/w
% w/w















Formulation contains




any one of the below



Active Ingredients
active ingredients







Cyclosporine
 0.01-0.1



Tacrolimus
 0.01-0.1



Phentolamine
0.001-1%



Testosterone
0.001-5%



DihydroTestosterone
0.001-5%



Testosterone propionate
0.001-5%



Compound of Formula
  0.001-0.1%



(Ia)




Compound of Formula
  0.0002-0.05%



(IIa)












Excipients





Silky Wax 10
5
5



Carbomer, Carbopol
0.5-1.0
0.5-1.0



980





Sodium Hydroxide
q.s.
q.s.



Glycerin
4-6
4-6



Mineral Oil
 8-12
 8-12



Water
q.s. 100
q.s. 100




















TABLE 7B









Delivery System
Gel



Quantity
% w/w








Formulation contains anyone



Active Ingredients
of the below active ingredients







Cyclosporine
 0.01-0.1



Tacrolimus
 0.01-0.1



Phentolamine
0.001-1%



Testosterone
0.001-5%



Dihydro Testosterone
0.001-5%



Testosterone propionate
0.001-5%



Compound of Formula (Ia)
  0.001-0.1%



Compound of Formula (IIa)
  0.0002-0.05%



Excipients




Elastomer 10
q.s. 100



Cyclomethicone 5-NF
20-30



Iisopropyimyristate
0.5-3  










Example 3

Table 8 illustrates an example of an emulsion formulation according to certain embodiments of the present invention.












TABLE 8










Delivery System












Emulsion
Emulsion











Quantity












% w/w
% w/w















Formulation contains any




one of the below active



Active Ingredients
ingredients







Cyclosporine
 0.01-0.1



Tacrolimus
 0.01-0.1



Phentolamine
0.001-1%



Testosterone
0.001-5%



DihydroTestosterone
0.001-5%



Testosterone
0.001-5%



propionate




Compound of Formula
  0.001-0.1%



(Ia)




Compound of Formula
  0.0002-0.05%



(IIa)












Excipients





Emulsifier 10
0.5-5
0.5-5



Mineral Oil
0.5-5
0.5-5



Sodium Chloride
0.5-1
0.5-1



Glycerin
0.5-2
0.5-2



Water
q.s. 100
q.s. 100










Example 4

Table 9 illustrates active pharmaceutical ingredients (API) according to the embodiments of the present invention.











TABLE 9







Typical concentration




range in


API
Examples
Ophthalmic products







Immunosuppressant
Cyclosporine A,
 0.001-0.4%



Cyclosporine analogs



Alpha-adrenergic
Phentolamine
 0.001-2%


antagonist




Steroids
Testosterone,
 0.001-5%



Dexamethasone,




Prednisolone



EP-2 agonists
Compound of Formula
 0.001-0.1%



(Ia)




Compound of Formula
0.0002-0.05%



(IIa)




Compound of Formula
 0.001-0.1%



(IIIa)



Muscarinics
Pilocarpine
  0.1-6.0%


Prostaglandins
Bimatoprost, Latanoprost
 0.001-0.1


Alpha-agonists
Brimonidine, Compound
 0.001-1%



of Formula (IVa);




Compound of Formula




(Va); Compound of




Formula (VI); Compound




of Formula (VIIa),




Compound of Formula




(VIIIa)



Antibiotics/anti-
Gatifloxicin
  0.1-1%


infectives




Anti-inflammatory
Ketorolac
 0.01-1%



Steroids



Beta Blockers
Timolol
 0.05-0.5%









Example 5

Table 10 illustrates an example of a spray formulation according to certain embodiments of the present invention.










TABLE 10








Delivery System











Spray
Spray
Spray









Quantity











% w/w
% w/w
% w/w












Formulation contains anyone of


Active Ingredients
the below active ingredients





Cyclosporine
 0.01-0.1


Tacrolimus
 0.01-0.1


Phentolamine
0.001-1%


Testosterone
0.001-5%


Dihydro Testosterone
0.001-5%


Testosterone propionate
0.001-5%


Compound of Formula (Ia)
  0.001-0.1%


Compound of Formula (IIa)
  0.0002-0.05%










Excipients





Silmogen Carrier
q.s. 100
q.s. 100



Talc
2-5




Dimethiconol Blend 20


1-5


Elastomer 10

5-15
 5-15


Cyclomethicone 5-NF


q.s. 100









Example 6

Table 11 illustrates an example of a stick formulation according to certain embodiments of the present invention.










TABLE 11








Delivery System











Stick
Stick
Stick









Quantity











% w/w
% w/w
% w/w












Formulation contains anyone of the


Active Ingredients
below active ingredients





Cyclosporine
 0.01-0.1


Tacrolimus
 0.01-0.1


Phentolamine
0.001-1%


Testosterone
0.001-5%


Dihydro Testosterone
0.001-5%


Testosterone propionate
0.001-5%


Compound of Formula (Ia)
  0.001-0.1%


Compound of Formula (IIa)
  0.0002-0.05%










Excipients





Beeswax
10-20

10-30


ST-Wax 30
 8-12

 5-10


Lanolin
 5-10




Cetyl Alcohol
 5-10




Castor Oil
q.s. 100

q.s. 100


Jojoba Seed Oil


 5-10


Silky Wax 10

5-15



Cyclomethicone 5-NF

q.s. 100



Caprylic/capric triglyceride

5-15



Mineral Oil


 5-10


Isopropylmyristate

5-15









Example 7

Table 12 illustrates an example of an emulsion formulation according to the embodiments of the present invention.










TABLE 12








Delivery System











Emulsion
Emulsion
Emulsion









Quantity











% w/w
% w/w
% w/w












Formulation contains anyone of


Active Ingredients
the below active ingredients





Cyclosporine
 0.01-0.1


Tacrolimus
 0.01-0.1


Phentolamine
0.001-1%


Testosterone
0.001-5%


Dihydro Testosterone
0.001-5%


Testosterone propionate
0.001-5%


Compound of Formula (Ia)
  0.001-0.1%


Compound of Formula (IIa)
  0.0002-0.05%










Excipients





Emulsifier 10
0.5-5
0.5-5
0.5-5


Mineral Oil

0.5-5



Vegetable oil
0.5-5




Almond Oil


0.5-5


Dimethiconol blend 20
q.s. 100

q.s. 100









Example 8

Table 13 illustrates the compositions according to the embodiments provided herein, which were used for in vivo assays.












TABLE 13









Component
Concentration (w/w %)











Formulation #
1
2















Compound of
0.11




Formula (VIIIa)





Compound of

0.1



Formula (IVa)





Dimethiconol 40
QS 100%
QS 100%










An in vivo pilot study was conducted using 4-[(S*)-1-(2,3-Dimethyl-phenyl)-ethyl]-1H-imidazole (Compound of Formula (VIIIa)) (0.11% w/w) and 3-[(1S)-1-(1H-imidazol-4-yl)ethyl]-2-methylbenzyl 2-methylpropanoate (Compound of Formula (IVa) (0.1% w/w) in dimethiconol 40. Eight normotensive DB rabbits (pigmented) were divided into 2 groups of 4. Formulations were instilled in the right eye (volume 35 uL). Tonometric measurements were conducted at 0, 2, and 4 hours.

Claims
  • 1. A composition comprising an active pharmaceutical ingredient and a silicone excipient.
  • 2. The composition of claim 1, wherein said active pharmaceutical ingredient is an immunosuppressant, a vasodilator agent, an anti-inflammatory agent, an EP2 receptor agonist, a muscarinic receptor agonist, a prostaglandin analog, a vasoconstrictor agent, or an anti-infective agent.
  • 3. The composition of claim 1, wherein said composition is an ophthalmic pharmaceutical formulation.
  • 4. The composition of claim 1, wherein said active pharmaceutical ingredient is an immunosuppressant.
  • 5. The composition of claim 1, wherein said active pharmaceutical ingredient is a vasodilator agent.
  • 6. The composition of claim 1, wherein said active pharmaceutical ingredient is an anti-inflammatory agent.
  • 7. The composition of claim 1, wherein said active pharmaceutical ingredient is an EP2 receptor agonist.
  • 8. The composition of claim 1, wherein said active pharmaceutical ingredient is a prostaglandin analog.
  • 9. The composition of claim 1, wherein said active pharmaceutical ingredient is a vasoconstrictor agent.
  • 10. The composition of claim 1, wherein said active pharmaceutical ingredient is an anti-infective agent.
  • 11. The composition of claim 1, wherein said silicone excipient forms part of a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, fourth silicone excipient blend or a fifth silicone excipient blend.
  • 12. The composition of claim 11, wherein said first silicone excipient blend comprises a mixture of dimethicone and dimethiconol.
  • 13. The composition of claim 11, wherein said second silicone excipient blend comprises a mixture of cyclopentasiloxane and a dimethicone cross polymer.
  • 14. The composition of claim 11, wherein said third silicone excipient blend comprises a mixture of polydimethylcyclosiloxanes.
  • 15. The composition of claim 11, wherein said fourth silicone excipient blend comprises a mixture of alkylmethyl siloxane copolyol, isostearyl alcohol and 1-dodecene.
  • 16. The composition of claim 11, wherein said fifth silicone excipient blend comprises a mixture of stearyloxytrimethylsilane and stearyl alcohol.
  • 17. The composition of claim 1, further comprising a salt, a tonicity agent, a lipid excipient or a thickening agent.
  • 18. A method of treating an ophthalmic disease in a subject in need thereof, said method comprising administering to said subject an active pharmaceutical ingredient and a silicone excipient.
  • 19. The method of claim 18, wherein said ophthalmic disease is glaucoma.
  • 20. A method of improving vision in a subject in need thereof, said method comprising administering to said subject an active pharmaceutical ingredient and a silicone excipient.
  • 21. A non-aqueous composition comprising an active pharmaceutical ingredient and a silicone excipient.
  • 22. The non-aqueous composition of claim 21, wherein said active pharmaceutical ingredient is an immunosuppressant, a vasodilator agent, an anti-inflammatory agent, an EP2 receptor agonist, a muscarinic receptor agonist, a prostaglandin analog, a vasoconstrictor agent, or an anti-infective agent.
  • 23. The non-aqueous composition of claim 21, wherein said composition is an ophthalmic pharmaceutical formulation.
  • 24. (canceled)
  • 25. (canceled)
  • 26. (canceled)
  • 27. (canceled)
  • 28. (canceled)
  • 29. (canceled)
  • 30. (canceled)
  • 31. The non-aqueous composition of claim 21, wherein said silicone excipient is a first silicone excipient blend, a second silicone excipient blend, a third silicone excipient blend, fourth silicone excipient blend, a fifth silicone excipient blend, a sixth silicone excipient blend or a seventh silicone excipient blend.
  • 32. (canceled)
  • 33. (canceled)
  • 34. (canceled)
  • 35. (canceled)
  • 36. (canceled)
  • 37. (canceled)
  • 38. (canceled)
  • 39. (canceled)
  • 40. (canceled)
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 13/410,828, filed Mar. 2, 2012, which claims priority under 35 U.S.C. §120 to U.S. Provisional Patent Application Nos. 61/448,899 filed on Mar. 3, 2011, 61/529,553 filed on Aug. 31, 2011, 61/565,447 filed on Nov. 30, 2011, and 61/448,890 filed on Mar. 3, 2011. This application is also a continuation-in-part of U.S. patent application Ser. No. 13/411,059, filed Mar. 2, 2012, which also claims priority under 35 U.S.C. §120 to U.S. Provisional Patent Application Nos. 61/448,899 filed on Mar. 3, 2011, 61/529,553 filed on Aug. 31, 2011, 61/565,447 filed on Nov. 30, 2011, and 61/448,890 filed on Mar. 3, 2011. The disclosure of the entirety of the preceding applications are hereby incorporated herein by reference.

Provisional Applications (8)
Number Date Country
61448899 Mar 2011 US
61529553 Aug 2011 US
61565447 Nov 2011 US
61448890 Mar 2011 US
61448899 Mar 2011 US
61529553 Aug 2011 US
61565447 Nov 2011 US
61448890 Mar 2011 US
Continuation in Parts (2)
Number Date Country
Parent 13410828 Mar 2012 US
Child 13972070 US
Parent 13411059 Mar 2012 US
Child 13410828 US